Microfluidic Approaches for Investigating Aggregated Forms of Disease-Related Proteins by Condado Morales, Itzel
Microfluidic Approaches for
Investigating Aggregated Forms of
Disease-Related Proteins
Itzel Condado Morales
Department of Chemistry
University of Cambridge
This dissertation is submitted for the degree of
Doctor of Philosophy
St John’s College September 2018

I would like to dedicate this thesis to the two women that have inspired and encouraged me
throughout my life: my mother and my granny. Thank you for your support, hard work, and
specially your love. All that I am, or hope to be, I owe to you.
Quiero dedicar esta tesis a las dos mujeres que me han inspirado e impulsado toda la vida:
mi madre y mi abuelita. Gracias por su apoyo, esfuerzo, y especialmente por su amor. Todo
lo que soy, o espero ser, se lo debo a ustedes.

Declaration
I hereby declare that, except where specific reference is made to the work of others, the
contents of this dissertation are original and have not been submitted, in whole or in part,
for consideration for any other degree or qualification in this, or any other university. This
dissertation is my own work and contains nothing which is the outcome of work done
in collaboration with others, except as specified in the text and acknowledgements. This
dissertation contains fewer than 60,000 words including appendices, bibliography, footnotes,
tables and equations.
Itzel Condado Morales
September 2018

Acknowledgements
I would like to thank Professor Tuomas Knowles for his invaluable guidance and insightful
discussions, and for giving me this opportunity to participate in such exciting work. I would
also like to thank Dr. Thomas Müller, who has been an amazing mentor and friend to me,
thank you for your guidance and feedback. I must also thank Professor Chris Dobson for
allowing me to work in the Centre for Misfolding Diseases. Finally, I also thank Professor
Adriano Aguzzi for welcoming me in his lab.
I have collaborated with a huge amount of talented people during my PhD, and I am
really grateful to Dr. Manuela Pfammatter, Dr. Simone Hornemann and Rita Moos, for
the collaborative work in the prion project, and all your feedback. Catherine Xu, Sean
Chia and Dr. Benedetta Maninni, for collaborating with me and allowed me to expand the
applications of my project. Dr. Pavan Challa for being instructive with the optics for FRET.
Dr. Christopher Taylor and Dr. Maria Andreasen, for the nice collaboration and feedback
with microdroplets experiments. Sam Ness, for his advice in protein purification. Raphaël
Jacquat and Quentin Peter, your coding efforts are highly appreciated for me and many others.
I would also like to thank all the CMD members, especially the Knowles group, for making
the lab such a nice place to work in. This piece of work would have not been possible without
the financial support of CONACYT and Cambridge Trust.
I would like to thank the rigorous proofreading and feedback of Dr. Thomas Müller,
Dr. Aviad Levin, Dr. Janet Kumita, Sam Ness and Tom Scheidt. Thank you all. I am also
very grateful to my examiners, Dr. Francesco Aprile and Dr. Lisa Cabrita, for the valuable
discussion and comments about the content of this thesis.
I could not have completed this work without the support of my family and friends in and
outside Cambridge. Thank you Ana, for being there for me in my best and worst moments.
Thank you Oscar, Sam, Mathias, Maya, Ula, Tom, Tadas, and many others, for our great
friendship. Nelly and Jose Manuel, who have been great friends to me despite the distance.
To my brother and my father for supporting me always. To Raphaël, for your emotional
support over this period: thank you for being you and for making me happy, you are amazing.

Abstract
The self-assembly of soluble proteins is a common phenomenon observed in nature. It
ranges from the formation of functional biomaterials, such as actin filaments and tubulin
microtubules that form the cytoeskeleton, to the abnormal deposition of aberrant aggregates
that lead to disease. There are nearly 50 diseases currently associated with protein misfolding
and amyloid formation, among them several neurodegenerative disorders such as Alzheimer’s,
Parkinson’s and prion diseases. Recent evidence indicates that the most toxic species are the
low molecular weight oligomers formed during the onset of the aggregation process. These
oligomeric species are commonly difficult to analyse due to their low abundance, transient
nature and heterogeneity in their structure. In fact, prions, known to be associated with
transmissible spongiform encephalopathies, have not yet been fully characterised as parts
of the prion composition seem to lose infectivity through various in vitro purification and
isolation procedures.
In nature, non-homogeneous solution conditions and molecular crowding are key fac-
tors as there might be multiple species associated with the disease. However, traditional
biophysical techniques allow the study of biomolecules under ideal conditions, such as
high concentrations and monodisperse size distribution. Furthermore, among the limitations
of the traditional methods are the sensitivity as well as the sample preparation, which in
some cases may require to chemically modify the molecule. In this thesis, I describe the
development of a sensitive label-free method to enable the study of protein complexes and
proteins under biologically relevant environment, such as brain homogenates, by combining
immunochemistry with microfluidic strategies.
In this thesis I describe the development of Immuno Diffusional Sizing (IDS), a method
that combines diffusional sizing with the sensitivity and specificity of immunoassay detection.
In Chapter 3, I explain the optimisation of the devices developed to size a range of particle
sizes in heterogeneous mixtures, from small protein monomers to large aggregates. IDS is a
label-free method capable of sizing proteins down to the nano- and picomolar concentrations,
in complex solutions. The applications of this method to monomeric and aggregated forms
of disease-related proteins are described in Chapter 4.
xIDS has been applied to study the Prion Protein (PrP) in its native and infectious forms.
Furthermore, I studied of the proteinase resistant form (PrPres) extracted from the brains of
infected mice specimens. IDS was applied for studying disease-relevant species, such as
intrinsically disordered proteins, e.g. α-Synuclein (aSyn) and Aβ40, and their respective
oligomers. Another advantage of this method is its applicability for studies of brain aSyn
from transgenic overexpressing mice (OVX). Furthermore, I explore the potential of IDS
for the study of post-translational modifications (PTMs) of specific proteins, such as the
ubiquitination of aSyn in vitro.
The efforts performed during this work to achieve TR-FRET detection on-chip are
described in Chapter 5. A comparison of two commercial immunoassays was performed
in order to determine the suitability for its adaptation from a platereader to a microfluidic
device. The design and adaptation of an optics platform for FRET detection on-chip is also
discussed.
My research on the mechanisms of the molecular chaperone αB-Crystallin (aBC) is
described in Chapter 6. I investigated the aggregation process of insulin in the presence
of aBC. I have used a combination of bulk techniques to study the kinetics of the systems,
as well as microfluidics to generate microdroplets that allow the direct observation of rare
nucleation events leading to protein aggregation.
Overall, in this work I describe the development of a novel microfluidic technique, its opti-
misation and application to multiple systems related to protein misfolding diseases, including
prions and intrinsically disordered proteins. Purification of the sample is not necessary to
study the target protein because the detection of the target protein after diffusional separation
is made with a sandwich immunoassay, which allows to study disease-related proteins under
native conditions in a label-free manner, which is usually difficult with traditional sizing
techniques. The applications of this technology could be expanded to characterise other
antigens in body fluids, like cerebrospinal fluid (CSF) of blood serum.
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Chapter 1
Introduction
1.1 Protein folding and misfolding
Proteins are one of the four main macromolecular constituents of cells, together with carbo-
hydrates, lipids and nucleic acids. They are long polymer chains formed by amino acids. The
long chain alone is not functional unless it acquires the correct, three-dimensional structure.
The protein folding problem is the question of how these amino acid chains fold to acquire
their native tertiary structure [1]. The number of possible configurations grows exponentially
with chain length [2]. Nevertheless, as described by the Levinthal paradox [3], protein
folding is not a random search of configurations until the protein reaches the correct one, as
this path would take a long time and protein folding occurs typically in the order of 10−2
seconds [4]. It is thought to be rather via a restricted folding pathway, that leads to a state of
minimal energy. All the possible pathways with their respective energies for a given protein,
can be described in a funnel shaped energy landscape (Figure 1.1) which maps all possible
conformations with their corresponding energy levels [5].
The correct protein folding is even more difficult in vivo due to the crowded environment
in the cell, in which the macromolecule concentrations can be around 0.3-0.4 g/ml [6].
Despite this harsh conditions, the cell has its own mechanisms to prevent protein misfolding,
such as chaperone activity, proteasome clearance and transcriptional/translational regulation
[7]. On the other hand, these protective mechanisms may become deficient with aging,
oxidative or metabolic stress, or even the presence of genetic mutations. Malfunction of
the protein homeostasis can lead to diseases. Usually, the standard free energy associated
with the amyloid state is comparable or even more negative than the one of the native state,
as shown in Figure 1.1, but this is only true at protein concentrations above a critital value
(critical concentration) and depends also on activation barriers [8].
2 Introduction
Fig. 1.1 Schematic representation of an energy landscape for protein folding and aggregation, showing
the multiple states available for a polypeptide chain. The folding funnels are indicated in light
gray and are caused by intramolecular interactions, while the aggregation pathways are indicated
in dark gray and are determined by intermolecular protein interactions. The amyloid state might be
thermodinamically more stable compared to the native state even under physiological conditions [8].
Reproduced from [5].
The maintenance of proteome homeostasis (proteostasis) are key for a healthy cellular
environment. An integrated network of several hundred proteins formed mostly by molec-
ular chaperones, the ubiquitin-proteasome system (UPS) and autophagy system, are the
responsible of proteostasis [9]. The main roles of molecular chaperones include assisting
the nascent polypeptide chains to fold into their native state, assisting proteins to prevent
misfolding under cellular stress, aggregate dissociation and refolding of denatured proteins
[10]. Chaperones are also responsible to accompany terminally misfolded proteins to their
protein degradation system, composed by the UPS and autophagy driven vacuolar (lysosomal)
proteolysis [11]. The degradation system is also crucial for identifying misfolded proteins
which are targets of the UPS. The greatest risk factor for proteostasis capacity is ageing,
which may facilitate the pathogenesis of several diseases, among them neurodegenerative
disorders, type 2 diabetes, amyloidosis, cancer and vascular disease [9].
Although the self assembly of soluble proteins or peptides to insoluble fibres is often asso-
ciated with disease, it is also a key process to some functioning biological systems. Examples
are the formation of silk produced by spiders [12] and cytoskeleton formation as known from
1.1 Protein folding and misfolding 3
actin biofilaments and tubulin microtubules. In this case, the functional aggregation process
leads to the formation of biomaterials and nanostructures, a polymerisation process described
as a simple nucleation and growth, like crystallisation [13]. In other cases, however, when
proteins undergo unregulated aggregation, the process can lead to disease. Nowadays, nearly
50 diseases are known to be associated with aberrant protein self-assembly, which can be
broadly classified into a) neurodegenerative conditions, like Alzheimer’s and Parkinson’s
disease, b) non-neuropathic localised amyloidosis (e.g. type II diabetes and cataracts) and c)
non-neuropathic systemic amyloidosis, like lysozyme amyloidosis [8, 14].
The first inherited human disease whose molecular mechanism was associated with
protein misfolding was sickle cell anaemia, which is caused by a single mutation that changes
a glutamic acid into a valine in the haemoglobin polypeptide chain [15]. This mutation
gives rise to the formation of abnormal filaments that deform the erythrocytes and leads
to sickling [16]. In 1907, Alois Alzheimer described the presence of aggregates in the
post-mortem tissue of his patient, Auguste Deter [17]. Nevertheless, it was not until 1985
that the components of these plaques and tangles were characterised, and they were found to
consist mostly of amyloid-beta peptide (Aβ ) and hyperphosphorilated tau, respectively [18].
According to the Alzheimer’s association, in 2018 around 50 million people are affected
with Alzheimer’s disease worldwide. The impact of the disease in society is not only
economic, but also emotional, as the patient’s family has to deal with their loss of cognitive
function as the disease progresses [19]. Hence, the search for an effective diagnosis and
treatment for Alzheimer’s, and other protein misfolding disorders (PMDs) is arguably just as
important as other kinds of disease such as cancer or viral infections. As increasing evidence
implicates specific forms of Aβ are associated with neurotoxicity, some therapeutics aim
to target the disease by depleting cerebral Aβ levels [20]. Alternatively, some others aim
to slow-down the aggregation process by targeting the nucleation events and delaying the
formation of cytotoxic species [21].
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease just
after Alzheimer’s [22]. The hallmark of PD is the presence of Lewy bodies (LBs) and
Lewy neurites (LNs), which are intraneuronal inclusions mainly composed of α-Synuclein
(aSyn). Although the association of aSyn to PD was originally made because it is the major
constituent of LBs in the PD brains, its direct role in the disease was demonstrated by genetic
evidence that links several mutations in the gene encoding aSyn that can result in familial
forms of PD [23]. aSyn is a largely unstructured protein in solution, like many others in the
context of PMDs, which are often described as natively unfolded or intrinsically disordered
proteins (IDPs) [14].
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IDPs lack stable secondary and/or tertiary structures under physiologycal conditions in
vitro. This feature enables IDPs to participate in many signaling, regulation and control roles,
by binding to multiple partners [24]. Several IDPs are associated not only with PMDs but
also with other types of human disease, like cancer, cardiovascular disease and diabetes.
The protein conformational diseases of IDPs result from protein aggregation as well as
misidentification, missignaling and nonnative folding. IDPs, such as aSyn, the Aβ peptide
and tau protein are therefore the target for drugs to modulate protein-protein interactions.
However, PMDs are linked to both IDPs and globular proteins, as it is the case of lysozyme
and insulin, and in some cases to proteins with highly disordered regions, for example the
mammalian cellular prion protein (PrPC) [14].
Prion diseases or transmissible spongiform encephalopathies (TSEs) are fatal neurode-
generative disorders associated with a misfolded form (PrPSc) of the functional prion protein
(PrPC) [25]. Although the prevalence of TSEs is exceedingly rare compared to other neu-
rodegenerative disorders, they represent a fascinating challenge for science, medicine and
the public health system due to the fact that they are infectious, rapidly progressive, and
are always fatal [26]. The detailed structure of the infectious PrPSc remains to be solved
[27], mainly due to its lack of solubility and the loss of infectivity caused by the addition
of denaturants used to solubilise the aggregates [28]. This has made the study of prion
replication (PrPC → PrPSc) quite challenging. The lack of detailed structure of PrPSc and
a precise understanding of prion replication has limited the development of both, a very
sensitive diagnostic procedure for TSEs, and an effective therapeutic approach which reliably
overcomes the disease [29].
Another subtype of PMDs are the so-called amyloidosis. Some examples of these
human diseases are the systemic amyloidosis associated to lysozyme and injection-localised
amyloidosis induced by the subcutaneous administration of insulin. Unlike neurodegenerative
disorders associated to protein misfolding where the exact cause of the disease is poorly
understood, amyloidosis is a disease in which the protein aggregates are the direct agent
that impairs tissue function [30]. Both lysozyme and insulin are highly structured under
physiological conditions, with a low propensity to aggregate. However, the fibrillation
process of globular proteins occurs under conditions that may promote partial unfolding (e.g.
low pH and high temperature) as well as the presence of mutations that destabilises the native
state [31].
The common feature of PMDs is the accumulation of amyloids, a term that is now
used to describe aggregates that share a set of common biophysical properties, such as
low solubility of mainly highly ordered filamentous structures and the predominant cross
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Fig. 1.2 The structure of transthyretin (TTR) studied with five different biophysical techniques: a)
Histogram of STEM measurements, b) experimental (left) and simulated (right) X-Ray diffraction
pattern, c) AFM of the fibrils, d) the different atomic substructures of amyloid fibrils ordered by
hierarchy. Reproduced from [32]
beta-sheet quaternary structure [33, 34]. Amyloid structure is depicted in Figure 1.2 which
shows the structure of transthyretin (TTR) fibrils and the atomic substructures studied by
different biophysical techniques [32]. In some cases, the accummulation of fibrils is the
direct cause of the disease, like the case of cataract in the eye lens [35] but in the case of
neurodegenerative disorders the actual cause is less clear as well as the precise pathological
agents. However, increasing evidence shows that the oligomers/protofibrils may be the
most cytotoxic species that lead to neurodegeneration [36, 37]. Therefore, a good way to
understand the onset and development of the disease is to describe the mechanisms involved
in the aggregation process on a molecular level. Even though the fibrils are formed by one
protein component [38], analysis is complex due to the number of simultaneous processes
with multiple species involved.
1.2 The kinetics of amyloid formation
The Oosawa model was the first approach that described the protein aggregation process
in two steps, by using an analogy to the formation of crystals [39, 40]. The first step is the
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Fig. 1.3 The general mechanisms that describe the protein aggregation process. a) Primary nucle-
ation is the spontaneous formation of nuclei from soluble monomers. b) Secondary pathways are
either monomer-independent processes like fragmentation or c) monomer-dependent such as surface
catalysed nucleation. Reproduced from [43].
formation of nuclei (primary nucleation) followed by fibril/oligomer growth through filament
elongation. While this model describes an analytical solution to the formation of functional
amyloids, it does not explain the formation of pathogenic aggregates. A heterogeneous
(secondary) nucleation mechanism, in which the surface of a polymer catalyses the formation
of new nuclei, was suggested to describe the aggregation of haemoglobin in sickle cell
disease with an analytical solution for the early-time approximation [41].
The main difference between functional and aberrant amyloid growth, is the presence
of the secondary processes. In functional amyloid growth, the rate of nuclei formation is
directly proportional to the concentration of monomer in solution. However, the pathways
for aberrant aggregation of proteins are more complex. The presence of surface catalysed
nucleation as well as fibril fragmentation, generates more nuclei and duplicates the number
of fibril ends for fibril elongation respectively, and complicates the analytical solution of
these systems. It was not until 2009 that a complete solution to the kinetic equations that
describe amyloid formation was formulated [42]. Overall, the mechanism can be described
with the following molecular steps as shown in Figure 1.3:
1. Primary nucleation: spontaneous formation of nuclei from soluble monomers.
2. Elongation: filament growth by addition of soluble monomers to the fibril’s ends.
3. Secondary nucleation: surface-catalysed formation of nuclei on pre-existing fibrils.
4. Fragmentation: formation of new fibrils by breakage of fibrils.
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Fig. 1.4 a) Structure of ThT and b) Congo Red dyes. c) Upon binding to amyloid fibrils, ThT emits a
fluorescent signal.
The mechanism describes the aggregation of the Aβ42 peptide, the protein involved in
Alzheimer’s disease [44]. It has also made it possible to study the kinetics of Aβ aggregation
in the presence of inhibitors such as molecular chaperones [45] and small molecules [21, 46].
The analysis of the experimental data is performed by determining the change in fibril mass
concentration, normally with the addition of dyes like thioflavin T (ThT) [47] or congo red
(Figure 1.4), but the latter is used less often as it has been shown to bind not only to amyloid
fibrils but native proteins too [48]. Intrinsic protein fluorescence derived from the fluorescent
amino acids phenylalanine, trypthophan, and tyrosine, can also be used to study the changes
in conformation of proteins [49, 50]. However, the use of intrinsic fluorescence is limited by
the requirement of high concentrations of the respective protein.
ThT fluorescence is triggered upon binding to beta-sheet structures (amyloid fibrils) as
shown in Figure 1.4. The mechanism of ThT binding is not totally understood but it has been
suggested that ThT can form micelles which adhere to the hydrophobic surface of fibrils,
and therefore enhances its fluorescence which can be detected by excitation at 450 nm and
emission with a maximum at 482 nm [47]. Since the dye binds specifically to amyloid fibrils,
it cannot detect the early formation of nuclei in the aggregation process or the presence of
pre-fibrillar aggregates.
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1.2.1 The toxic oligomers
In the past decade, research indicates that pre-fibrillar aggregates are the main cytotoxic
agents for several human amyloidogenic systems [51], for instance Aβ [52], aSyn [37], and
the prion protein [53]. It is clear that these species are transient and structurally heterogeneous,
making it difficult to study the relation between their structure and toxicity [54]. The main
problem in studying the most toxic species lies in the ability to isolate and stabilise them.
Therefore, their proper analysis would require a sensitive detection in real-time [55].
The heterogeneous structure and composition of the oligomers may be due to the different
pathways that lead to the formation of these pre-fibrillar species [56]. In some cases the
pathways are enhanced by solution conditions such as pH and protein concentration or even
certain mutations, whereas in others aggregation may proceed via competing pathways. The
oligomers can be on-pathway species that lead to fibril formation, or off-pathway particles
that work only as a reservoir of monomers.
The toxicity of oligomeric species is determined by both hydrophobicity and size, with
the most toxic ones having small size and high hydrophobicity [57]. The mechanisms of
toxicity are poorly understood but some studies suggest that the hydrophobic surface of
the oligomers can mediate aberrant interactions with other proteins which would result in
their functional impairment and sequestration [58]. Furthermore, the oligomers can disrupt
artificial as well as biological lipid membranes, compromising the integrity of the cell
[59]. Although there is evidence that in some cases mature fibrils are toxic, the toxicity
of pre-fibrillar aggregates makes them the primary pathogenic species responsible for the
onset of disease [60]. Although there is a debate whether amyloid formation is in fact a
mechanism of protection against more toxic species [61], in some diseases like systemic
amyloidosis the accumulation of fibrils is the direct cause of organ dysfunction [62], hence
protein aggregation is a process that should be avoided for the preservation of biological
function [60].
The oligomers that form during the amyloid formation process can be formed either during
primary nucleation or secondary nucleation processes. Kinetic measurements carried out
with computer simulations indicate that the amyloid formation follows a two-step mechanism
that involves oligomers [63]. The primary nucleation occurs through an oligomer with the
correct size born during rare fluctuations and thus most oligomers are not of the right size
to produce fibrils and will eventually dissociate to monomers. The formation of oligomers
through secondary nucleation is determined by the amount of fibrils formed, which grows
exponentially with time during the early times of aggregation [64]. The oligomers generated
through secondary nucleation are similar to those by primary nucleation, with a highly
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disordered structure and low growth rate. Since the toxicity is linked to protein oligomers
or their generation process, over the time course of an aggregation reaction the secondary
nucleation generates many orders of magnitude more oligomers than primary nucleation.
This may suggest that in order to interfere with the aggregation process in a disease context,
it would be necessary to derive inhibitors that supress the adsorption of monomers onto the
surface of protein fibrils (secondary nucleation) [63].
The structural characterisation of oligomeric species during amyloid formation has been
particularly challenging due to their transient, low abundant and heterogeneous nature. Their
identification has been made by means of indirect experimental data, enriching the samples
with other stable oligomers, fluorescence-based techniques, AFM in combination with FT-IR
and single-molecule fluorescence approaches [65]. However, it would be desirable to have a
highly sensitive technique that could provide structural information of the oligomers in the
biologically-relevant state.
1.3 Structural techniques
NMR and X-Ray crystallography are among the most powerful techniques to characterise
macromolecular structures with high-resolution. Nevertheless, they both have some draw-
backs. X-Ray needs the isolation of pure crystals to obtain the detailed information of the
structure, and the crystalline structure may not resemble completely the one in solution [66].
NMR has the potential to determine structures at the atomic level, as well as molecular
dynamics, but it is limited to proteins of up to 35 kDa, mostly because of sensitivity loss and
increasing complexity of spectras of bigger structures [67]. Recent advances in solid-state
NMR have made it possible to study large monomeric proteins and protein complexes, but
its applicability is limited by the ambiguous assignment of the NMR signals in large systems
[68].
Mass spectrometry is also one of the fundamental tools used for proteomics in molecular
and cell biology. In combination with other separation techniques, such as liquid or gas
chromatography, it can be used to study protein-protein interactions as well as to provide a
full description of the protein composition of multiple organisms [69]. The main limitation
of the technique is that for some samples, an additional separation step prior to analysis is
required, and the time-scale of the experiment. Therefore, studying transient samples in
biologically relevant environment is difficult with mass spectrometry.
Cryo-electron microscopy (CryoEM) has emerged as a powerful technique for structural
biology. In comparison with NMR and X-Ray crystallography, it has less limitations for
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the amount and purity of sample required. Despite the fact that the technique is close to
atomic resolution for large complexes, solving small specimens remains challenging [70].
Furthermore, the samples have to be frozen and remain surrounded by water, this mantains
biological conditions to a certain extent [71]. Another drawback of CryoEM is the long time
required for data collection, which makes the throughput for screening slower than for X-Ray
crystallography [72]. Despite its limitations, CryoEM has already made it possible to study
amyloid fibrils from patient-derived material [73] as well as the structure of a protofibril
formed by a fragment of the prion protein [74].
Some other traditional methods are performed to study protein- protein interactions
on a daily basis in almost every biophysical research laboratory. The sodium dodecyl-
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) is one of the most commonly
used techniques as it provides information on the molecular weight of proteins and protein
complexes [75, 76]. By addition of antibodies after the gel separation (Western Blot analysis),
it can be used to detect specific proteins in a complex mixture. However, the analysis of
protein aggregates with SDS-PAGE has shown to be unreliable as there is evidence that
oligomeric states can be affected by the denaturing process [77, 78]. An alternative to SDS-
PAGE is to perform electrophoresis of proteins in the absence of SDS or other denaturing
agents, i.e. under “native” conditions, method known as native PAGE [79]. Under such
conditions the separation depends on the individual charge of the protein and the pH of the
separation, and hence it requires to optimise the protocol for the respective sample. Size
exclusion chromatography (SEC) coupled to multiple detection techniques can be used to
study oligomeric states of proteins [80, 81]. SEC allows to determine the hydrodynamic
radius of proteins as the molecules are retained in the column according pore size of the
resin [82]. Nevertheless, the detection method should be sensitive enough to detect low
concentration of samples, as it is the case of the on-pathway oligomers.
Other biophysical approaches can be used to study proteins in solution, such as Isothermal
Titration Calorimetry (ITC) and Surface Plasmon Resonance (SPR). They can provide
important information, such as binding constants, as well as kinetic and thermodynamic
parameters [83]. However, they have a number of limitations such as interference from
solution conditions, high levels of sample consumption (ITC) and potential surface artefacts
(SPR) [84].
A traditional sizing technique is Analytical Ultra Centrifugation (AUC), which allows the
determination of monomeric and oligomeric protein sizes [85]. However, the application of
AUC to heterogeneous mixtures has its limitations, since deconvolution of the sedimentation
equation of the mixture becomes quite complex [86]. Dynamic Light Scattering (DLS) is
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a more rapid technique than AUC, and perhaps the most popular for determining particle
size in solution. It measures the change in the light trajectory (scattering) after the incoming
monochromatic light hits particles in Brownian motion [87]. Nevertheless, it can be prob-
lematic for heterogeneous mixtures. Since large particles scatter more light than the small
ones, usually the result of a polydisperse mixture is biased towards the large particles. The
preparation of the sample should therefore be made carefully in order to avoid dust particles
or other contaminants, and the concentration should be adjusted so that the scattering intensity
is at least 10 times that of the solvent (good signal-to-noise ratio). Therefore a poor sample
preparation may lead to errors in the measurement.
An obvious alternative to the methods presented above is the use of microfluidics, mostly
because of its potential to miniaturise different biological systems which enables high-
throughput processes and a favourable scaling of physical forces.
1.4 Microfluidics
Microfluidics is the science and technology of manipulating fluids in channels with di-
mensions of tens of micrometres [88]. The use of microchannels allows the integration,
miniaturisation and automation of various processes. However, the main characteristic of
microfluidics is the physics that govern the processes at the microscale, such as the mass
transport which is dominated by viscous forces rather than inertial ones, with a laminar flow
behaviour. This laminar flow generates some advantages over macroscopic tools, such as
faster diffusive heat and mass transfer at the microscale, as well as enhanced spatiotemporal
resolution and subcellular resolution [89]. Overall, microfluidic technology presents many
advantages for studying biological systems, among them [90]:
• Laminar flow. Enables the manipulation of fluids with high precision and a purely
diffusive mixing.
• Small volumes. Small volume confinement not only reduces sample-consumption, but
also it can effectively amplify the limits of detection of the biomolecules or cells under
investigation.
• High throughput analysis. The miniaturisation of chemical and biological processes
allows to integrate them in parallel in a single device, which is particularly useful for
screening on-chip.
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• Integration. The small size, planar geometry and transparency of microfluidic devices
make them suitable to integrate with many other analysis techniques.
1.4.1 Origins and applications
Microfluidic technology has its origins back in the 1950s, with the development of ink-jet
technology and the necessity to dispense volumes in the order of nano and sub-nanolitres
[91]. With the development of genomics in the 80’s and the need to develop a technology
to integrate and parallelise multiple processes, microfluidics could provide the solution for
these problems. A second driving force for the development of microfluidic systems came
from the US Department of Defense, which in the 1990s aimed to develop microsystems for
the detection of chemical and biological threats [88].
During the 80’s and 90’s most of the microfluidic fabrication was made with silicon
substrates, but at the end of the 90’s with the development of soft-lithography methods of
poly-di-methyl-siloxane (PDMS) the technology enabled the fabrication of relatively cheap
devices. This is the most popular procedure currently used [89].
The variety of microfluidics applications is quite broad, from its use in basic research in
chemistry, biology and physics, to applications in diagnosis and biomedical devices. The
main drawback of microfluidics was perhaps that the technology was limited to laboratory
with the specific equipment to use these devices, mostly pumps and specialised optics
equipment. However, nowadays efforts are done to make this technology more accessible
to people outside the laboratory. Several companies sell microfluidic solutions in the form
of benchtop equipment where the user does not have to do more than loading the sample.
Another example is Point-Of-Care (POC) applications, which needs the development of
diagnosis devices that are easy enough to use by the side of the patient by clinicians, nurses
or by themselves, and not necessarily a microfluidic expert.
The use of microfluidics in the life sciences has become a crucial element, particularly
in cell biology and protein biophysics. One of the advantages of microfluidics over other
technologies is the low-volume of sample consumption and the enhancement of sensitivity.
Advances in microtechnologies have supported areas as diverse as biomarkers in diagnostics,
biomaterials and drug discovery [92]. The use of microdroplets, for example, has enabled
key developments in cell biology as it allows quantitative analysis of single cells [93] as well
as high throughput phenotyping and genotyping at the single cell level [94].
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1.4.2 The fluid flow at the microscale
The physics in microfluidic channels is analogous to those in electronics, with a flow of
fluid and a flow of electrons, respectively. But unlike with microelectronics, the laws of
physics scale more dramatically in microfluidics. Perhaps the most important change is that
in the mass transport in microfluidics inertial forces are negligible, and viscous forces are
the predominant ones [91]. The relative importance of the various phenomena ocurring in
fluidic physics can be expressed in a series of dimensionless numbers [95]. One of them, the
Reynold’s number, relates the inertial to viscous forces:
Re =
fi
fv
=
ρU0L0
η
(1.1)
where U0 is the flow velocity of the fluid, ρ its density, L0 a typical length scale (e.g. the
channel width) and η the fluid viscosity. The Reynold’s numbers in microfluidic devices are
small, between the order of 10 to 10−6. Under these conditions the flow is laminar, but as the
Reynold’s number increases, turbulence destabilises it.
The Péclet number relates advective and diffusive transport rates. If τD is the time it takes
for particles to diffuse over a distance L1, then
τD =
L21
D
(1.2)
where D is the diffusivity D = kBT6πηRH for particles with hydrodynamic radius RH , kB the
Boltzmann constant and T the temperature in Kelvin. The time τA for particles to advectively
cross a distance L2 is
τA =
L2
U0
(1.3)
and the Péclet number is the ratio between τD and τA:
τD
τA
=
L21
D
L2
U0
(1.4)
In the case L1 = L2 = L0, the Péclet number can be expressed as Pe =
L0U0
D . But in the
case of a diffusion channel, where L1 is the channel width w and L2 is the channel length L,
the Péclet number can be expressed as
Pe =
U0w2
LD
(1.5)
14 Introduction
In the world of microfluidics, the low-Re results in mixing that depends on diffusion
alone. This purely diffusive mixing may represent a problem when rapid mixing is required,
for example in a chemical reaction, but may be desirable in some other cases, as it can be
used for particle sizing among other applications.
1.5 Aims
The aim of this thesis is to develop a microfluidic platform that integrates the diffusional sizing
method along with immunochemical assays that, due to their use of antibodies, provides
specific and sensitive detection. The technique, which I named “Immuno Diffusional Sizing
(IDS)", aims to be used as an alternative or a complement to the methods mentioned in the
introduction. IDS is applicable to a range of disease-relevant proteins and proteins under
a biologically relevant environment, including insulin, the Aβ peptide, aSyn and PrP. It
enables the sizing of protein aggregates, such as oligomers, which as explained previously,
are particularly challenging to study due to their low abundance and transient nature.
Chapter 2
Materials and Methods
2.1 Microfluidic device fabrication and flow control
2.1.1 Microfluidic device fabrication
All photomask devices were designed using the Autodesk AutoCAD software platform.
The microchannels were printed on acetate masks (Micro Lithography Sevices, Essex, UK).
Microfluidic channels were fabricated using standard soft-lithography techniques [96] as
illustrated in Figure 2.1.
Masters were made by spin-coating a small volume (∼3 ml) of SU-8 photoresist (Mi-
croChem Corp., Rugby, UK) and placed onto the centre of a circular silicone wafer (3"
diameter, Micro Chemicals, Germany). The spin speed was chosen based on the desired
height and SU-8 used and, for these experiments, SU-8 3025 and 3050 were used to create 25
µm and 50 µm thick layers respectively, using a spin speed of 3000 rpm. After the coating,
the wafer was a soft-baked at 90◦ C for 12 (SU-8 3025) to 25 (SU-8 3050) min. Following
this, the photomask patterned with the desired design was fixed to the wafer using a press
with a UV-transparent cover. The wafer was then exposed to a UV-light emitting diode
(UV-LED) [97] at 1000 mW for 50 s. The resultant master was then baked again (90◦ C),
this time for 5 min (for both SU-8 3025 and 3050). After this, the non-crosslinked SU-8
was removed using a developing agent (Propylene glycol methyl ether acetate, PGMEA) by
placing the wafer in a glass evaporation dish, filled until the wafer is covered with PGMEA.
The dish was then agitated for 3 (SU-8 3025) to 5 (SU-8 3050) min, before being rinsed with
first PGMEA and then isopropyl alcohol (IPA). The wafer was then blown dry with nitrogen,
before being stored in a covered petri dish. For all diffusional-sizing experiments, the height
of the channels was measured with a Bruker Dektak® profilometer (Coventry, UK).
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Fig. 2.1 Schematic description of microfluidic device fabrication with soft-lithography.
The master was then covered with a mixture of poly-di methyl siloxane PDMS (Dow,
Corning) with crosslinker (Sylgard 184, Dow Corning) in a 10:1 (w/w) ratio, and degassed
for 15 min. For black PDMS devices, a small amount of carbon nanopowder (Sigma Aldrich,
UK) was added to the PDMS mixture and centrifuged for 15 min at 2000 rpm before pouring
it into the master. The mixture in the master was baked for 1.5 h at 65◦ C. The set of PDMS
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Fig. 2.2 Schematic description of flow rate controlled by syringe pumps. The flow rates are selected
with the pumps software. The syringes are attached to the pumps. In this example, the samples are
injected through the device inlets by positive displacement of the pumps.
devices was then removed from the master using a scalpel, connections were made with
biopsy punches (0.75 mm diameter), and then the devices were plasma bonded to glass slides
using oxygen plasma (Diener Electronic Femto plasma oven). In this case, the devices and
glass slides were exposed to oxygen plasma for 10 s at a power of 40 mW and a pressure of
3 mbar. For binding PDMS devices to quartz slides instead, the exposure to oxygen plasma
was for 30 s at a power of 40 mW.
In order to prevent protein-adsorption to the PDMS channels, extended plasma oxidation
of the PDMS surface was conducted, which created a silanol-rich hydrophilic layer [98]. The
treatment was performed after the devices were bound to glass/quartz slides, exposing to
oxygen plasma for 500 s at a power of 80 mW and a pressure of 3 mbar.
2.1.2 Microfluidic flow control
The flow in the channel was controlled by applying positive displacement at both inlets
(Figure 2.2), buffer and analyte, by using two syringe pumps (Cetoni neMESYS, Cetoni
GmbH, Korbussen, Germany) at a flow rate of 60 µl/h insulin and 540 µl/h buffer for the
first device designed. In the second generation device, H-filter, total flow rates in the range of
80-400 µ l/h were used, with the analyte flow 1940 of the total flow rate. The buffer and protein
solutions were injected through a 1 ml plastic syringe (HSW) connected with plastic tubing
(0.38 mm ID, 1.09 mm OD) to the PDMS device. Both fractions, 1 and 2, were collected by
connecting the device with a low-binding tube with plastic tubing. The collection time varied
between 30 min and 3 h, according to the sample volume needed and flow rate used.
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2.2 IDS calibration and testing protocols
2.2.1 Insulin immunodetection
Lyophilised human insulin was supplied by Sigma-Aldrich UK, and used without further
purification. An insulin stock of 10 mg/ml was prepared in 50 mM HCl, filtered though a
22 µm filter and the concentration was measured in the NanoDrop 2000c (ThermoFisher
Scientific) by UV-absorbance at 276 nm, using an extinction coefficient value of 1 for 1 mg
ml−1 [99]. Insulin hexamer was prepared as described previously [100]. For the detection
of human insulin, the commercial HTRF® immunoassay kit was used, purchased from
Cisbio Bioassays (Codolet, France). Briefly, insulin samples (2 µl per well) were mixed
with the antibody-pair (18 µl per well) and incubated for 30 min at room temperature. The
TR-FRET readings were performed in Clariostar® (BMG Labtech) always simultaneously
with a standard curve, made of 1:2 serial dilutions starting from 2 nM insulin.
2.2.2 Calibration measurements of the diffusional separation device
Different flow rates were measured by injection of mQ water with positive displacement
with two syringe pumps (Cetoni neMESYS, Cetoni GmbH, Korbussen, Germany), with
microfluidic flow sensors (Elveflow® Elvesys Innovation Centre, Paris, France) connected
at the outlets of the device. Colloids with 25 nm radius were bought pre-labelled with
fluorescein from ThermoFisher as 2.5% by volume suspensions. They were diluted to 0.1%
by volume in mQ water solutions for measurement. Images were acquired every 5 min, at a
flow rate of 80 µl/h for each device, with colloids at 38 µl/h and water at 42 µl/h.
2.3 IDS of Prion Proteins
Experiments with PrP were carried out at the facilities of the Institute of Neuropathology,
University of Zürich, Switzerland.
2.3.1 Recombinant mPrP
Full length murine prion protein (mPrP23−231) was recombinantly expressed and purified as
previously described [101–103]. The PrPC monoclonal POM antibodies were purified as
previously described [104]. POM19 was labelled with the donor fluorophore (Eu-chelate)
and POM1 was labelled with the acceptor fluorophore allophycocyanin (APC) acceptor as
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previously reported [105]. The TR-FRET measurements were performed in a platereader at
620 and 665 nm after a 1 h incubation (37◦C) and after overnight incubation (4◦C) for better
signal stabilisation.
2.3.2 Prion inoculation
30 µl of 0.1% of RML6 (passage 6 of Rocky Mountain Laboratory strain mouse-adapted
scrapie prions) BH was injected intracerebrally into PrPC overexpressing Tg20 mice [106].
Mice were monitored three times per week, and daily close to terminal stage. Mice had
unrestricted access to food and water. Prion-infected mice were sacrificed at the terminal
stage of prion disease. All animal experiments were conducted in strict accordance with
the Rules and Regulations for the Protection of Animal Rights (Tierschutzgesetz and Tier-
schutzverordnung) of the Swiss Bundesamt für Lebensmittelsicherheit und Veterinärwessen
BLV. All animal protocols and experiments performed were specifically approved for this
study by the responsible institutional animal care committee, namely the Animal Welfare
Committee of the Canton of Zurich (permit numbers ZH040/15). All efforts were done to
minimise animal discomfort and suffering.
2.3.3 Mouse brain homogenates preparation: ZH1, Tg20 and RML-
infected Tg20.
Brains were prepared by Petra Schwarz, homogenisation was performed by myself.
The mouse brains from ZH1 PrP0/0 and Tg20 mice were washed with ethanol (2x, 70%)
and sterile PBS (4x). Then they were homogenised in an eight-fold amount of sucrose (0.32
M) to prepare a 10% wt. solution with the Ribolyzer tube (speed 6.5, 4x 35s). After the
first homogenisation step the tubes were cooled down on ice and the step was repeated 2
more times. The Tg20 and RML-infected Tg20 brains used for subsequent PK-digestion
were homogenised in PBS only because the sucrose interfered with the PK-digestion. The
homogenates were centrifuged (700g, 3 min). The supernatant was collected for further use
and the pellet was discarded. Before injection into the microfluidic device, the BH samples
were diluted to 1% on tris buffer (50 mM, pH 7.4, 1% wt. BSA).
2.3.4 PK-digestion of RML-infected Tg20 brain homogenate
Conducted by Riita Moos.
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Uninfected and RML-infected Tg20 10% BH were diluted to 2% in PBS. 10 µl of
proteinase K (1000 µg/ml, C f = 50 µg/ml) was added to 190 µ l of 2% BH. The mixture was
incubated for 2 h at 37◦C under continuous shaking at 650 rpm. The digestion was stopped
by addition of PMSF to a final concentration of 3 mM and incubation was performed for
15 min with continuous shaking at 750 rpm. The samples were analysed by Western Blot
(Appendix A). For better results, the sample was injected freshly after PK-digestion directly
into the microfluidic device. See Appendix A for details on the digestion conditions.
2.3.5 Details of the microfluidics experiments
The flow in the channel was controlled by applying positive pressure at both inlets, buffer
and analyte, by using two syringe pumps (Cetoni neMESYS, Cetoni GmbH, Korbussen,
Germany) at total flow rates in the range of 80-400 µl/h, the analyte flow being 1940 of the
total flow rate. For recombinant mPrP, a flow rate of 200 µl/h was used with the 200 µm
width device. For all brain PrP samples, tests with both devices (200µm and 80µm width)
were conducted, at flow rates of 200µl/h and 80µl/h, respectively. The buffer and protein
solutions were injected through a 1 ml syringe (HSW) connected with plastic tubing (0.38
ID, 1.09 OD) to the PDMS device. Both fractions, 1 and 2, were collected by connecting the
device to a low-binding tube with plastic tubing. The collection time varied between 30 min
and 3 h, according to the sample volume needed and flow rate used. The auxiliary stream was
the tris buffer with BSA (0.1%), which prevents the proteins sticking to the PDMS channels.
2.3.6 Detection of PrPC with TR-FRET
Recombinant mPrP and Tg20 BH TR-FRET: aliquots of the samples extracted from the
outlets (25 µl) were mixed with the antibody-pair, Eu-labelled POM1 and APC-POM19 (5
µ l each) in a 384-well plate. After 10 min shaking (300 rpm, RT) the sample was incubated
at RT for another 50 min before measuring in a Paradigm® platereader (Molecular devices,
San Jose, CA, USA). The labelled antibodies and protein were diluted in Tris (50 mM, pH
7.43) with BSA (1%).
RML-infected Tg20 non-digested and digested BH treatment for ELISA: in order to
disassemble the fibrils before detection with ELISA, aliquots of the samples extracted from
the outlets (162 µl) were mixed with 21 µl NaOH (0.5M, C f =57.9 mM) and incubated for
10 min at RT under continuous shaking (700 rpm). 24 µl of neutralising buffer (NaH2PO4)
was then added and incubated for 10 min at RT under continuous shaking (700 rpm).
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2.3.7 Sandwich ELISA protocol for PrP
This protocol was developed by Daniel Heinzer (Institute of Neuropathology, University
Hospital Zürich, Switzerland). Experiments carried out by myself.
The desired wells of a 384-well high binding transparent plate were coated overnight
at 4◦C with 50 µl of the capture antibody POM1 (400 ng/ml) in coating buffer (0.1M
Na2CO3/NaHCO3). The plate was aspirated 4 times in washing buffer (PBS, 1% Tween)
before addition of 100 µl/well of blocking buffer (5% TopBlock in PBS-T) and incubated
for 2 h at RT. The plate was aspirated four times in washing buffer before addition of the
samples. A standard curve of recombinant mPrP was prepared by 1:2 serial dilutions starting
with 5 ng/ml of mPrP. PrP samples were added (50µ l) to the desired wells. After incubation
of the samples for 1.5 h at RT, the plate was washed four times with PBS-T buffer. 50 µl of
the detection antibody, biotin-labelled POM19, was added in sample buffer (1% TopBlock in
PBS-T) at a concentration of 1:5000 and incubated for 1 h at RT. The plate was washed four
times with the washing buffer and 50 µ l of avidin-HRP was added (1:1000 in sample buffer)
and incubated for 1 h at RT. The plate was again washed four times with the washing buffer
before addition of 50 µ l/well of stabilised TMB. After a 15 min incubation the reaction was
stopped by addition of 1 N H2SO4 and the absorbance read at a wavelength of 450 nm.
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2.4.1 Amyloid beta monomer expression and purification
Conducted by Sean Chia and Ewa Klimont.
Expression and purification of the recombinant Aβ40 were carried out as previously
described for Aβ42 [21]. In brief, Aβ40 was expressed in the E. Coli B21Gold (DE3) strain
(Stratagene, La Jolla, CA) and purified by sonicating the bacterial cells and dissolving the in-
clusion bodies in urea (8M), followed by ion exchange in batch mode on a diethylaminoethyl
cellulose resin. The fractions were lyophilised and further purified using a Superdex 75HR
26/60 column (GE Healthcare, Chicago, IL) and eluates were analysed using SDS-PAGE
for the presence of Aβ40. The fractions containing the recombinant protein were combined,
frozen using liquid nitrogen, lyophilised in either sodium phosphate buffer (20 mM, pH 8.0)
for preparing Aβ40 monomers or ammonium acetate (50 mM, pH 8.5) for producing Aβ40
oligomers, and stored at -80◦C.
Before injection into the microfluidic device, solutions of the monomeric peptide were
prepared by re-dissolving the lyophilised Aβ40 peptide in guanidinium hydrochloride (6M).
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The monomers were purified from any oligomeric species and salts using a Superdex 75
10/300 GL column (GE Healthcare, Chicago IL) at a flow rate of 0.5 ml/min, and eluted
in sodium phosphate buffer (20 mM, pH 8). The centre of the peak was collected and the
concentration of the peptide determined from the absorbance of the integrated peak area
(ε280=1490M−1cm−1).
2.4.2 Amyloid beta oligomers preparation
Performed by Dr Benedetta Mannini and Sean Chia.
The preparation of Aβ40 oligomers was carried out as previously described [107]. In
brief, lyophilysed Aβ40 peptide (1 mg) was dissolved in hexafluoroisopropanol, HFIP (300
µl, 100%) overnight at 4◦C and the solvent was then allowed to evaporate under a gentle
flow of N2. The peptide was resuspended in DMSO (100 µl/mg) and sonicated twice (10
min, RT). The Aβ40 peptide in DMSO was then diluted in sodium phosphate buffer (20
mM, pH 6.9) with ZnCl2 to a final concentration of 100 µM of Aβ40, incubated at 20◦C
for 20 h and centrifuged (15000xg, 15 min, 20◦C). The pellet containing the oligomers was
resuspended in phosphate buffer (20 mM, pH 6.9) with ZnCl2 (200 µM).
2.4.3 Immunodetection assay of Amyloid beta monomers and oligomers
The samples were collected separately from both outlets of the device and treated as indicated
in the protocols of Cisbio Bioassays Inc.(Codolet, France). The immunoassays readings
were performed on a CLARIOstar® platereader system (BMG Labtech GmbH, Ortenbeg,
Germany) in white polystyrene plates with volumes of 20 µl per well. The incubation time
before reading was 90 min (RT) for the Aβ40 (monomer and oligomers) at RT. The labelled
antibodies, as well as the proteins, were diluted in the buffer: NaH2PO4 (50 mM) pH 7.4,
BSA (0.1%). Monomeric Aβ40 was used for the standard curve of the Aβ40 monomer
experiment and the respective oligomer for the sizing of each of them, in serial 1:2 dilutions
with a starting concentration of 2 nM.
2.4.4 Isolation of on-pathway Amyloid beta oligomers by SEC
Performed by Sean Chia.
Aggregation of Aβ40 (60 µM) in phosphate buffer (20 mM, pH 7.4) was carried out
by placing the 96-well plate at 37 ◦C under quiescent conditions in a plate reader (Fluostar
Optima, BMGLabtech, Offenburg, Germany). The aggregation process was followed with a
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sample with ThT. The control fluorescence was measured through the bottom of the plate
with a 440 nm excitation filter and a 480 nm emission filter. A sample was taken after 1.6 h
incubation and run again through a Superdex 75 10/300 GL column (GE Healthcare, Chicago
IL) at a flow rate of 0.5 ml/min, and eluted in sodium phosphate buffer (20 mM, pH 7.4) to
separate the oligomeric fraction from the monomer, as previously described [44].
2.4.5 aSyn expression and purification
Performed by Catherine Xu.
Wild-type (WT) aSyn was purified from Escherichia coli BL21 cells, transformed with
the pT7-7 plasmid encoding the protein. Point mutations of the original plasmid were
used for the mutants (G51D and H50Q). Cells were grown in 2xYT (37 ◦C, 180 rpm) with
ampicillin (100 µg/ml), induced with IPTG (1 mM), incubated overnight (28 ◦C, 180 rpm),
and harvested by centrifugation in a Beckman Avanti J25 centrifuge with a JLA-8.1000 rotor
for 30 min at 6238 x g (Beckman Coulter UK Ltd., High Wycombe, UK). The cell pellet
was resuspended in 10 mM Tris-HCl (pH 7.7), 1 mM EDTA, complete protease inhibitor
cocktail (1 tablet/40 ml; Roche, West Sussex, UK), and lysed by sonication. Following
centrifugation (JA-25.50 rotor, 39191 x g, 30 min), the supernatant was boiled for 20 min
and centrifuged (39191 x g, 30 min). Streptomycin sulphate was added to the supernatant to
a final concentration of 10 mg/ml (30 min incubation at 14 ◦C and centrifuged (39191 x g, 30
min). Ammonium sulphate was added to the supernatant to 361 mg/ml and stirred at 4 ◦C for
30 min. The mixture was centrifuged (39191 x g, 30 min), and the pellet resuspended in 25
mM Tris-HCl (pH 7.7), dialysed overnight, and loaded onto a HiLoadTM (TM in superscript)
26/10 Q sepharose high performance column (GE Healthcare Ltd., Little Chalfont, UK) and
eluted at 3˜50 mM NaCl with a salt gradient from 0 M to 1.5 M NaCl over 600 ml. Selected
fractions were subsequently loaded onto a Superdex 75 26/60 (GE Healthcare Ltd.) and
eluted in PBS. Protein concentration was determined by absorbance at 275 nm, using an
extinction coefficient of 5600 M−1cm−1.
2.4.6 aSyn oligomer preparation
Conducted by Catherine Xu.
The preparation of oligomeric aSyn, for WT and mutants (G51D, H50Q), was carried
out as previously described [108]. In brief, lyophilised wildtype aSyn was resuspended
in PBS buffer (pH 7.4) to a final concentration of 12mg/ml and filtered (0.22 µm cut-off)
immediately before incubation at 37 ◦C for 20-24 h without shaking to avoid the conversion
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into fibrils. The fibrillar species were removed by ultracentrifugation (1 h, 90 000 rpm) and
the excess of monomer was removed by filtration (with 100-kDa cutoff membranes). The
concentration was determined from the absorbance (ε275=5600M−1cm−1) given in monomer
equivalents (mass concentration). The oligomers were stable for days at RT and were used
for injection into the device at a maximum of 2 days after their production.
2.4.7 OVX Brain homogenates preparation
Brain homogeneate samples were prepared by Dr Sarah Threllfel at the University of Oxford
facilities (Oxford Parkinson’s Disease Centre, Department of Physiology, Anatomy and
Genetics, Oxford, UK).
Brains (aSyn overexpresser (SNCA-OVX), WT aSyn and knockout (Snca−/−)), were
washed 2x in ethanol 70% and 4x in sterile phosphate buffer saline (PBS) in the original
falcon tubes. Brains were homogenised in 0.32 M Sucrose (prepared in distilled water),
or lysis buffer (from the Cisbio HTRF aggregated aSyn kit), with the Ribolyser. 2 brains
and the eight-fold amount of sucrose (or lysis buffer) were homogenised to prepare 10%
homogenate (868.8 mg brain + 7819.2 µl sucrose, speed: 6.5, time: 4x 35 s). After the first
homogenisation step the tubes were cooled down on ice and the step was repeated 2 times.
The homogenates were collected in 50 ml falcon tubes. The sample was centrifuged at 700 g
for 3 min. The supernatants were aliquoted in 1 ml eppendorf tubes (500 µ l each) and frozen
at -20◦C. The samples were shipped to the Department of Chemistry, Cambridge, on dry ice.
2.4.8 In vitro translation and In vitro ubiquitination of aSyn
In vitro translation and ubiquitination reactions carried out by Shai Zilberzwige.
His-tagged aSyn expresses in cell-free in vitro transcription (4 h, 37◦C). In vitro ubiquiti-
nation (IVU) was carried out by mixing 1/10 of the In vitro translation (IVT) reaction with
E3 ligase specific to aSyn and incubation for 1 h at 37◦C. The ubiquitinilation was confirmed
using western blots with antibodies against aSyn and ubiquitin.
2.4.9 Immunodetection of aSyn
The detection of monomeric as well as brain aSyn was performed with the alphaLISA® kit
purchased from PerkinElmer (PerkinElmer,Seer Green, UK). Given their light sensitivity,
these reagents were stored and handled under filtered and subdued lighting. The protocol
used was the 2-steps addition. The immunoassay readings were performed on a CLAR-
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IOstar® plate reader system (BMG Labtech GmbH, Ortenbeg, Germany) in 384-well white
polystyrene plates with volumes of 100 µl per well.
The detection of aSyn oligomers was conducted with the TR-FRET kit purchased
from Cisbio (Codolet, France). The immunoassay readings were performed on a CLAR-
IOstar® plate reader system (BMG Labtech GmbH, Ortenbeg, Germany) after 1 h incubation
at 25◦C, in 384-well white polystyrene low-volume plates.
2.5 Towards TR-FRET on-chip detection
The TR-FRET and alphaLISA kits for insulin were purchased from PerkinElmer.
TR-FRET measurements were performed in a Clariostar® platereader at 25◦C on cycles
of 15 min. alphaLISA measurements were performed as indicated by the PerkinElmer
protocol with the 2-step protocol: mixing the antibodies, sample, and acceptor beads together
first, incubating, then adding donor beads for final incubation.
2.5.1 Microfluidic experiments
Microfluidic devices were prepared as indicated in Section 2.1, using the protocol for black
PDMS devices bound to quartz slides.
2.5.2 TR-FRET Platform
Light from a 340 nm Mounted LED (Thorlabs M340L4) was passed through an aspherical
lens of focal length to obtained a collimated beam. This beam was incident on a dichroic filter
cube, which consists of an excitation filter (Semrock FF01-340/22-25) centred at a wavelength
340 nm and a dichroic mirror (Semrock FF347- Di01). The light is focused onto the sample
flowing in a microfluidic device by an infinity corrected UV objective lens (magnification
10X, numerical aperture = 0.25). The fluorescence from the sample is collected through the
same objective, passed through an emission filter (Semrock FF01-625/26 or FF01-661/20-25)
centred at a wavelength of 625 and 661 nm respectively, and finally focused onto a EMCCD
camera (Evolve Delta Photometrics) by an air-spaced achromatic doublet lens (Thorlabs
ACA254-200-UV) of focal length 200 mm. The exposure time used in our experiments was
about 500-1000 ms. See Appendix A for spectra details.
Propidium iodide (Sigma Aldrich, UK) was diluted in water to a concentration of 1 mM,
and used as a calibration dye.
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2.6 Chaperone influence on insulin aggregation
2.6.1 Materials
Bovine insulin was purchased from Sigma Aldrich and it was used without any further
purification. The concentration of insulin in solution was determined by absorbance at 276
nm, using an extinction coefficient value of 1 for 1 mg ml−1 [99]. All inorganic chemicals
were obtained from Sigma Aldrich unless otherwise specified. In all cases, mQ H2O (18.2
mΩ) was used to prepare the aqueous solutions.
2.6.2 Expression and purification of alpha B-Crystallin
Expression and purification method adapted from the protocol of Justin Benesch’s laboratory
(University of Oxford, United Kingdom).
Standard heat-shock transformation of chemically competent bacteria
A human aBC gene (codon-optimised for E. coli expression) in a kanamycin resistant
pET24d(+) vector (5 µl DNA) was mixed with BL21-Gold cells (Agilent, 50 µl). The
mixture was kept on ice (30 min) and then it was heat-shocked by placing half the tube
in a 42 ◦C water bath (45 s). The mixture was kept on ice (2 min) before adding it into
LB media (250 µl, no antiobiotic) and grown in the incubator (180 rpm, 37◦C, 45 min).
The transformation was spread onto agar plates (containing kanamycin, 50 µg/ml) and
incubated overnight (37 ◦C, 180 rpm). One of the colonies was chosen and it was placed
in LB media (12 ml) previously inoculated with kanamycin (50 mg ml−1, 12 µl). After
overnight incubation (37 ◦C, 180 rpm), the cells were mixed in a 1:1 ratio with a glycerol
solution (50% v/v glycerol/water). The glycerol cell stock was separated in eppendorf tubes
and frozen in liquid N2 for further storage at -80 ◦C.
Expression in LB and OverExpression Media
The pre-culture was prepared by addition of frozen cells from the glycerol stock with a sterile
pipette tip into LB-media, (150 ml) supplemented with kanamycin (50 mg ml−1, 150 µ l) and
the mixture was incubated overnight (180 rpm, 37 ◦C).
Kanamycin (50 mg ml−1, 1 ml) and pre-culture (20 ml) were added to each litre of
LB-media, and the cells were incubated (37 ◦C, 180 rpm) until the OD was more than 0.6
but less than 0.7 (approx. 3.5 h). Then a solution of Isopropyl β -D-1-thiogalactopyranoside
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(IPTG, 1M, 1 ml) was added to each flask and the mixture was incubated for longer (4 h, 37
◦C, 180 rpm). The cells were harvested by centrifugation (7000 rpm, 15 min, 4 ◦C). The
supernatant was discarded and the pellet resuspended on ice, in 25 ml lysis buffer for each
litre grown. The lysis buffer was a solution of Tris-HCl (40 mM, pH 8.6), lysozyme (0.1 mg
ml−1), DNAse1 (a few milligrams) and complete protease inhibitor cocktail (1 tablet for 2
litres of culture). The cells were lysed by sonication (16 cycles of 15 s spaced 45 s) before
being centrifuged (15000 rpm, 30 min, 4 ◦C). The supernatant was collected and filtered.
As the yield of aBC in LB-media was low, a second protocol was performed and optimised
using OvernightExpress media (OE). Kanamycin (50 mg ml−1, 500 µl) and cells from the
pre-culture (10 ml) were added to 500 ml batches of OE, to incubate during the day (37 ◦C, 7
h, 180 rpm) and then overnight (30 ◦C, 180 rpm). The cells were harvested by centrifugation
in a Beckman Avanti J25 centrifuge (Beckman Coulter UK Ltd., High Wycombe, UK) with
a JLA-8.1000 rotor for 15 min at 7000 rpm at 4 ◦C. The supernatant was discarded and
the pellet was kept on ice and resuspended in 25 ml lysis buffer for each litre grown. The
cells were lysed by sonication (16 cycles of 15 s pulse, 45 s pause) before being centrifuged
(15000 rpm, 30 min, 4 ◦C). The supernatant was collected and dialysed against buffer A (20
mM Tris-HCl at pH 8.6 and 1 mM EDTA).
2.6.3 Purification with anion-exchange and size-exclusion chromatog-
raphy
Table 2.1 AEC elution gradient used in the purification of aBC.
Elution volume (ml) Buffer B percentage Flow rate (ml/min)
Volume of
collected
fractions (ml)
0 0 4 0
30 0 4 2
80 20 4 2
130 100 4 2
190 100 4 0
The protein was purified by Anion Exchange Chromatography (AEC) using a HiTrap Q
HP column (5 × 5 ml, GE Healthcare). The column was equilibrated with 2 column volumes
(50 ml) of water, NaCl (2M, 50 ml) and the buffer A. After filtration (0.22 µm pore diameter),
the sample was injected onto the column (10 ml/injection) using a 50 ml Superloop (GE
Healthcare) and eluted over a gradient of Buffer B (Tris-HCl 20 mM, pH 8.6, EDTA 1 mM
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and NaCl 1 M) as shown in Table 2.1. SDS-PAGE analysis was carried out to select the
suitable fractions (usually around 24-30) to be concentrated using a Vivaspin 20 concentrator
(MWCO 5 kDa, GE Healthcare).
A Superdex 200 PG column (GE Healthcare) was equilibrated with 2 column volumes
(CV) (240 ml) of ammonium acetate buffer (200 mM, pH 6.9). The sample was injected
onto the column using a 10 ml Superloop (GE Healthcare), eluted over 1 CV (120 ml) and
collected in 2 ml fractions. SDS-PAGE analysis allowed the suitable fractions to be pooled
and concentrated using a Vivaspin 20 concentrator (MWCO 5 kDa, GE Healthcare). The
final concentration of the protein was measured with a Nanodrop 2000 Spectrophotometer
(Thermo Scientific) at 280 nm (ε280 = 19000cm−1M−1).
2.6.4 Sample preparation for kinetics experiments
Solutions of monomeric insulin were prepared by dissolving the lyophilised insulin in 50 mM
HCl to a concentration of 10 mg ml−1, which corresponds to 1.74 mM. The monomer solution
was filtered and diluted with HCl (50 mM) to the desired concentration and supplemented
with 40 µM Thioflavin T (ThT) from a 1 mM stock. All samples were prepared in low binding
eppendorf tubes and kept on ice before use. Each sample was then pipetted into multiple
wells of a 96-well half-area, low-binding, clear bottom and PEG coating plate (Corning
3881), 150 µl per well, in the absence and the presence of different molar-equivalents of
aBC, and/or the presence of different equivalents of fibrils. In order to prevent evaporation
caused by the high temperature used to promote aggregation, all the unused wells were filled
with mQ water and the plate sealed with a foil cover.
2.6.5 Kinetic bulk assays
Assays were initiated by placing the 96-well plate at 60 ◦C under quiescent conditions in a
plate reader (Fluostar Optima, BMGLabtech, Offenburg, Germany). The ThT fluorescence
was measured through the bottom of the plate with a 440 nm excitation filter and a 480 nm
emission filter. The ThT fluorescence was followed for triplicates of each sample. The data
were analysed with the Amylofit web-based software [109].
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2.6.6 ThT spectral scan
ThT fluorescence spectral scans were measured with 20 µM ThT in the wavelength range of
470 - 550 nm using a 440 nm excitation filter. The error of the assay was calculated from
three independent replicate measurements of the microplate assay.
2.6.7 Transmission Electron Microscopy (TEM)
Samples for TEM were prepared on carbon support film, 400 mesh, 3 mm copper grids
(EM Resolutions Ltd., Saffron Walden, UK) and stained with 2% uranyl acetate (w/v). The
samples were imaged on a FEI Tecnai G2 transmission electron microscope in the Cambridge
Advanced Imaging Centre (CAIC, University of Cambridge, Cambridge, UK). The images
were analysed with the ImageJ software.
2.6.8 Microdroplet assays
Insulin aggregation reactions were carried out in microdroplets, by encapsulating water-in-
oil-emulsions using a microfluidic device with flow focusing geometry, with the protocol
modified from [110]. The different aqueous solutions were injected into the middle inlet
on the chip at a flow rate of 200 µl h−1. The carrier oil phase made of fluorinated FC-40
(Sigma) with 4% (w/v) fluorosurfactant FS-008 (Ran Biotechnologies, Beverly MA, USA)
was injected into the outer inlet at a flow rate of 300 µ l h−1 to generate droplets with a radius
of ∼50 µm. Fluid flow rates were controlled with a Cetoni neMESYS syringe pump (Cetoni
GmbH). The microdroplets were collected into Rectangular Borosilicate capillaries (CM
Scientific), and the capillaries were sealed with wax plugs to prevent sample evaporation.
Before imaging the capillaries containing samples at different fibril dilutions, capillaries were
aligned on a glass slide for imaging. The aligned capillaries were placed on the automated
motorised stage of a custom-built epifluorescence laser microscope, and covered with a
custom-built incubator heated to 60 ◦C to induce aggregation. The incubator was used in
order to observe the position of the droplets over time with brightfield images taken for each
timepoint and position, with a brightfield LED light source on top of the incubator. To track
aggregate formation within the droplets, fluorescent images were acquired every 15 min for
approximately 72 h using laser excitation at 445 nm (diode laser MLD445, Cobolt).

Chapter 3
Development of Immuno Diffusional
Sizing
3.1 Introduction
3.1.1 The diffusional sizing method
The diffusive transport of molecules in microfluidic devices has been applied to both the
separation and analysis of biomolecules [111–120]. For example, the H-filter [113] can be
used to separate large from small molecules according to their diffusion coefficients, but it
can also be applied to the analysis of molecular interactions [118]. The diffusional behaviour
can be exploited to estimate the hydrodynamic radius RH , which for a biomolecule can be
defined as the radius of a hard spherical particle that diffuses at the same rate as that molecule.
Diffusional sizing can be used to resolve heterogeneous mixtures of proteins by determin-
ing the diffusion profile of molecules at different positions of the channel, and comparing it
to simulations made for different RH [111]. Figure 3.1 a shows the microfluidic device design
and the reading positions for obtaining the diffusion profiles along the channel. This method
can be exploited to calculate binding constants and can be used in complex backgrounds
given that the molecule of interest is fluorescently labelled, as in this enhances sensitivity.
However, labelling of the analyte is in principle undesireable as the tag may modify the main
structure and disturb binding interactions [121, 122]. But diffusional sizing can in principle
be performed in a label-free manner, by using the intrinsic fluorescence property of proteins,
as long as there is just one protein component present in solution and the concentration is
high enough to be detected [97].
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a b
Fig. 3.1 Two different microfluidic diffusional sizing examples. a) The device allows to track the
diffusion profiles of particles in space and time, and b) native microfluidic diffusional sizing device,
where the biomolecules are separated by diffusion into a stream of buffer, and the label is added just
before detection. Reproduced from [111] and [112], respectively.
Another possibility to study proteins in a label-free manner is by addition of the label
after separation but just before detection, for example with fluorescence detection after elec-
trophoretic separation [123]. The separation by diffusion followed by fluorescent labelling
is known as native microfluidic diffusional sizing (nu-sizing) [112], and the device used in
nu-sizing is illustrated in Figure 3.1 b. This method has several applications, such as detection
of protein complexes, binding constants and direct measurements of protein unfolding [124].
The labelling is made with orto-phthalaldehyde (OPA) which reacts with primary amines and
thiols in aqueous alkaline medium to form fluorescent adducts [125, 126]. The use of OPA
therefore limits this method for solutions of one protein component only, as the reaction is
not specific and would target all primary amines, including those present in some buffers like
tris. The method requires the addition of a denaturing component to the labelling mixture
in order to guarantee that all the primary amine groups are exposed, making the labelling
quantitative. The fraction of diffused protein obtained experimentally is compared to the one
obtained with simulations, termed basis functions [127] to estimate the hydrodynamic radius
of the protein of study.
Another application example of diffusional transport is its use to separate aSyn fibrils
(large particles) from monomers (small particles) [120]. The device, shown in Figure 3.2
a, originally used to monitor the binding of small molecules to amyloid fibrils, works by
injecting the protein stream in the middle and buffer on the sides. In the microfluidic
channel, the particles in the sample stream can mix with the auxiliary buffer only by diffusion.
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Fig. 3.2 Illustration of the microfluidic diffusional separation used in the first experiments of IDS. a)
The sample is injected in the middle and auxiliary buffer on the sides, which run side by side in the
diffusion channel and are separated again in the end. b) AutoCAD design of the device and c) images
of fluorescently-labelled small and large colloids, at the different positions in the device. Reproduced
from [120].
Figure 3.2 c shows the aSyn monomers and fibrils at different positions of the device. At
the end of the diffusion channel, the monomers have completely diffused, while the fibrils
remain in the central stream, due the their smaller diffusion coefficient.
The technique of fluorescence resonance energy transfer (FRET), involves a donor
fluorophore in an excited electronic state, which transfers its excitation energy to an acceptor
fluorophore when they are in close proximity (<10 nm) through a non-radiative process
[128]. In this study, the diffusional sizing technique has been coupled to immunoassay
detection, which, do to the use of antibodies, makes the detection of the protein being sized
highly specific. Time-resolved FRET (TR-FRET) [129] uses separately labelled antibodies
with FRET donor and acceptor fluorophores. In the context of microfluidic technology, a
TR-FRET immunoassay could be a potential detection method as some of its characteristics
make it a suitable candidate for on-chip measurements.
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Fig. 3.3 Schematic description of TR-FRET assays. Left: FRET donor and acceptor labelled antibod-
ies come in close proximity upon binding to the same molecule, which enables FRET between the
fluorophores conjugated to the antibodies. The excitation is a single pulse and the FRET signal is read
in a time-resolved manner to eliminate the background fluorescence. Reproduced from [130].
3.1.2 Time-Resolved FRET
An obvious improvement to the nu-sizing method would be the addition of a specific label
that is innactive without the target, as this would allow the detection of proteins in complex
mixtures. Here, the method of choice for specific detection was the use of immunoassays, in
particular the time-resolved FRET (TR-FRET) immunoassay as it is a 1-step homogeneous
assay, which offers the possibility to be performed on-chip. Homogeneous Time Resolved
FRET (HTRF) [129] technology usually works with sandwiching antibodies, each of them
labelled with a FRET-donor and the other with a FRET-acceptor. The formation of the
immunocomplex brings the FRET pair into close proximity, and the intensity of the FRET
signal is directly correlated to the concentration of the analyte. The measurement is conducted
in a time-resolved way to eliminate any non-specific fluorescent signal from the background,
which enables sizing in complex biological samples without prior purification of the protein
or protein oligomeric species.
Time-resolved measurements are performed for the reason that FRET signals are influ-
enced by the fluorescence of the sample background. Therefore TR-FRET uses a rare earth
chelate as donor due to their long-lived fluorescent signals upon excitation by an energy
pulse [130] as shown in Figure 3.3. The excitation pulse is in the order of microseconds and
thus the background signal decays rapidly, and the detection of the FRET dependent signal is
measured after a time-delay, within a time window.
TR-FRET technology has multiple advantages over traditional immunoassays such as
enzyme-linked immunosorbent assay (ELISA), which is usually time-consuming and requires
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surface immobilisation and multiple washing steps that makes it quite complicated to adapt
into a microfluidic device. TR-FRET combines homogeneity, great signal stability and high
specificity with low-background interference [131]. Its multiple advantages confers this
technology great potential for its use with different body fluids such as CSF, blood, serum,
plasma, and saliva. However, as all immunoassays it has some drawbacks, for example the
limitation in dynamic range caused by the high-dose Hook effect. In systems where the
analyte concentration range is large, antigen concentration can go into excess, and both free
and bound analyte compete for the limited antibody binding sites, when the antibody pair
is added simultaneously [132]. This effect can be adverted by performing the assay with
multiple sample dilutions. Another limitation of TR-FRET assays is the detection of binding
distance up to 9 nm [133] due to FRET efficiency that decreases with increasing distance
[134].
3.2 Aims
The aim of this chapter is to provide an overview of the development and optimisation of
the device used for Immuno Diffusional Sizing (IDS). All the experiments mentioned in this
and the following two chapters, are for a device where diffusion happens on-chip, but all
immunoassays are made in bulk. The attemps to create a device for on-chip detection are
mentioned in Chapter 5.
3.3 Results and discussion
3.3.1 First generation device for Immuno Diffusional Sizing
Insulin is found as a zinc-coordinated hexamer under physiological conditions, but in the
absence of zinc it is found as a dimer [135]. Monomers, the active form of insulin, are pre-
dominant under acidic conditions [136]. The oligomeric states of insulin can be manipulated
through changes in the pH and the addition of various additives such as Zn2+, and thus it
was chosen as the model protein for diffusional sizing. The preliminary experiments of the
diffusional sizing post-separation were conducted with the device designed to separate fibrils
from monomers [120], shown in Figure 3.4 a. The device, works by injecting the protein
stream in the middle and auxiliary buffer on the sides, at a flow rate ratio of 1:10. At the end
of the diffusion channel (l = 9 cm, w= 300 µm), it is split into three equal parts (w= 100
µm) to collect the centre as a fraction non-diffused ( fnd) and the two sides as a separated
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Fig. 3.4 Schematic description of the IDS method using the first generation device. a) Design of the
device indicating the protein and auxiliary buffer inlets, diffusion channel and outlets that separate
the fractions diffused and non-diffused, for their analysis with the TR-FRET on a platereader. b)
Concentration profiles for reference species of known size obtained with simulations [127], observed
laterally from across the end of the diffusion channel. c) The Net FRET signal of the separated
fractions for insulin monomer, insulin in the presence of cell lysate and the insulin hexamer. The
error bars show the standard deviation of triplicate TR-FRET measurements of each sample. The
net FRET values are converted to concentration with a TR-FRET standard curve, and divided to
calculate the detected ratio ( fdfnd ). d) The corresponding hydrodynamic radius after interpolation of
the experimental detected ratio to the basis functions in b. Values in bar graph represent mean ± SD
of n = 3 experiments performed with different devices. One-way ANOVA P = 0.0001, followed by
Tukey’s HSD test ∗∗P < 0.002, ∗∗∗P < 0.0002.
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fraction diffused ( fd). Therefore, proof-of-principle experiments for immunodetection after
separation by diffusion were performed with this design, with the model protein insulin.
Both fractions at the outlet were collected separately, and the detection with TR-FRET
was performed in bulk, by mixing the fractions with the antibodies on a microwell plate
and readings were taken on a platereader. The Net FRET (DF%) for each of the separated
fractions reflects the signal to background of the assay
DF% =
RSample−RNeg control
RNeg control
×100, (3.1)
where RSample or RNeg control are an average of the ratio of the signal calculated for
each individual well, measured at two different wavelengths (620 nm and 665 nm) which
normalises the signal [129]:
R =
Signal665nm
Signal620nm
×104. (3.2)
Figure 3.4 c shows the net FRET signal of each of the fractions fnd and fd , for monomeric
insulin pure and with cell lysate, and the insulin hexamer. These signals are converted to
concentration with a TR-FRET standard curve, to calculate the experimental “detected ratio”.
This value is extrapolated to its corresponding hydrodynamic radius, with the simulated
concentration profiles of a range of particle sizes, shown in Figure 3.4 b.
The method presented here, which I named Immuno Diffusional Sizing, does not require
the use of fluorescently-labelled proteins, since the detection is made only after the protein
is diffusional-separated in the microchip (Figure 3.4 a). The TR-FRET provides then the
concentration of protein non-diffused and diffused (to the auxiliary buffer) as indicated in
Figure 3.4 c, or the experimental “detected ratio”. Finally, in order to estimate the protein
size, the “detected ratio" is extrapolated to its corresponding hydrodynamic radius with the
basis functions, simulations of the diffusion profiles for different particles of known size
(Figure 3.4 b).
The monomeric insulin test was carried out by running the device at 600 µl/h, flow rate
that worked well for small proteins. The size of monomeric insulin at a concentration of 22
nM and at pH 2 (1.17 ± 0.04 nm) was consistent with the previously reported size of 1.3 nm
[137] but the error in the size measurement (3.4%) would not allow the distinguishment of
species close in size, such as monomer from dimer. The sizing of the insulin monomers in a
complex mixture was also made by spiking it into 1% cell lysate, leading to the a size (1.68
± 0.06 nm) that may reflect a mixture of monomers, dimers and hexamers, as illustrated in
Figure 3.4 b. The mixture of species could be causd by the additives present in the cell lysate
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mixture. IDS was suitable to size the insulin hexamer (2.15± 0.07 nm) by stabilising it in the
presence of Zn2+ at a high concentration of insulin (70 µM) [100]. However, when attempts
to size higher molecular weight proteins were conducted, the device was not appropriate
leading to large errors among repeats.
One of the main limitations of the design was that there was no way to observe that the
flow rate of the protein remained centred in each and every device, as all the measurements
were conducted in a label-free manner. Sometimes the instabilities were caused by bubbles
present at the nozzle, but bubbles could be detected with a brightfield microscope. If there
was an irregularity on the glass or PDMS, which caused the flow to be modified, it was only
detected after doing the TR-FRET measurement as it seemed that there was more protein in
the fd than in the fnd . The other main problem was that the use of the 1:10 flow rate ratio
of protein to buffer caused fluctuations in the protein flow rate when low flow rates were
used. In this device, the analyte and the auxiliary fluid were loaded into syringes and the
solution flow rate was controlled by applying a positive pressure with two syringe pumps,
the fluctuations depend on the two pumps.
An alternative to the problem was to switch to the withdrawing mode rather than the
pulling. Usually, the pulling mode is preferred not only because the fluctuations in the flow
rate are less than in pushing mode, but also because it requires less sample volume and
only one pump to control the whole device. Nevertheless, as the detection with TR-FRET
was performed off-chip, it was still necessary to collect the two separated fractions from
the outlets. One alternative to solve this limitation was to use a “pulling-adaptor”, but this
had several drawbacks as with such a device it would have been complicated to collect the
separated fractions from the outlets. Therefore, a complete change to the separation device
was performed, making specific changes as shown in Figure 3.5 to make it suitable for sizing
small and large particles.
3.3.2 Physical considerations
Figure 3.5 shows a schematic description of the main changes introduced to the diffusional
separation device in order to optimise it for IDS. Among the main considerations made
for the new design was the fact that the samples in the diffusion channel were label-free,
therefore a geometry like the traditional H-filter [113] was chosen because it is the simplest
configuration. Unlike the old design, where the buffer separates in two streams that run on
the sides of the protein one, in the H-filter there are only two streams that move in parallel.
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Simplify the nozzle design
Optimal width and
length to diffuse
around 1/3rd of the
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Fig. 3.5 Schematic description of the changes introduced to the diffusional separation device for
optimisation. The inlets were changed to a geometry of 19:21 to avoid the errors caused by the flow
fluctuations. The nozzle was simplified to reduced the possibility of bubbles. The main diffusion
channel was adapted to have a fraction diffused of 1/3rd of the total protein, or fdfnd=0.5 . An intensity
ratio of 0.5 ± 0.1 does not affect the value of the calculated hydrodynamic radius (0.34 ± 0.07 nm).
In the contrary, at intensity ratios below 0.1, small changes affect the size of the radius drastically,
which can lead to errors in the size estimation. The outlets were simplified to a geometry of 50:50.
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Fig. 3.6 Three-dimensional simulations of the velocity profiles at four different positions in a T-sensor
indicated in A. Simulations were conducted over a large range of flow rates from 41.7 nl/s and 1 µ l/s,
and in all cases the velocity profiles, shown in B, had the same shape and relative magnitud. Velocity
is fully developed to 99% at 1423 µm. Adapted from [115].
The nozzle was also modified to make it simpler. The original design was wider and
usually several air bubbles were trapped on it; the main problem was the stream not being
perfectly centred because of small imperfections in the nozzle. Simulations of flow in
previous studies [115] showed that the velocity at the junction where the two inlet channels
meet was zero, but it increased rapidly until flow was fully developed (99% at a distance
of 1.4 cm) as shown in Figure 3.6. Since in all of our experiments the measurements were
collected at a distance of at least 10 cm, the nozzle should not make a difference.
The optimal length of the device was selected by considering that ideally fdfnd = 0.5, this
means 1/3rd of the total protein should be diffused at the end of the channel. As indicated
in Figure 3.5, an intensity ratio of 0.5 ± 0.1 does not change the value of the calculated
hydrodynamic radius. In the contrary, at intensity ratios below 0.1, small changes affect the
size of the radius drastically, which can lead to errors in the size estimation. The diffusion
coefficient is defined by the Stokes-Einstein equation:
D =
kBT
6πηRH
(3.3)
Where kB is the Boltzmann constant, T is the temperature in K, η is the viscosity of the
fluid and RH is the hydrodynamic radius of the particle. The displacement along the x-axis
(width, in this case) over which the concentration distribution softens is of the order of the
square root of 2Dt [138, 139], as illustrated in Figure 3.7. This means that
σ =
√
2Dt (3.4)
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Fig. 3.7 Simulations of fifteen random walks x(t), with origin and t = 0 and x = 0 with diffusivity
D = 1. The continuous curves are ±√2Dt. Reproduced from [138].
where σ is the width of the function, D is the diffusion coefficient and t is the time. The
time at which the particle is at the end of the diffusion channel is the residence time, which
could be estimated through
t =
lhwc
Q
, (3.5)
where l is the channel length, h is the channel height, wc is the channel width and Q is
the flow rate. For particles diffusing up to at least half the width of the buffer stream, that
represents σ = wc4 . By adding this expression to equation 3.4
w2c
16
= 2Dt. (3.6)
By substitution of the residence time (eq. 3.5) in equation 3.6, and re-arranging the terms:
l =
Qwc
32Dh
(3.7)
Equation 3.7 can be used to estimate the optimal length for diffusing particles from the
sample stream up to at least half the width of the buffer stream. Considering a particle of 1.5
nm radius, a channel height of usually 25 µm, a flow rate of 200 µl/h and a width of 200
µm, the total length of the channel would be of 103 mm. For a particle of 10 nm radius, with
the same device dimensions and flow rate, the optimal length would be of 685 mm. Since
the channel would be too long, a possibility is to make the channel width smaller, to 80 µm,
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flow at a lower rate, and then the channel length results in 109 mm. These measures are
reasonable for a device, and therefore two main designs were used with different widths, 80
µm and 200 µm width, each of them of 10 cm length and 25 µm height, with the 80 µm
being optimal to diffuse a particle of 10 nm radius to at least w4 , i.e. 30%.
The inlet was designed to be in a ratio of 19:21 protein buffer. The slight change in the
volume ratio was to avoid the errors produced by the fluctuations in the flow if the initial
state was at 50:50 exactly. The outlets were at a ratio of 50:50. The length of the inlets
and the outlets were designed to produce a resistance of the order of the diffusion channel.
The resistance in microfluidic networks can be calculated as analogous to electrical circuits
[140]. The pressure drop ∆p through a finite channel of length L can be calculated with the
following expression:
Q =
∆p
rH
, (3.8)
where rH is the hydraulic resistance [Pa/(m3/s)], and Q is the total volumetric flow
rate [m3s−1] [140]. Equation 3.8 is the Hagen–Poiseuille’s law simplified, and it relates the
pressure drop to the hydraulic resistance that for a circular channel with a radius R and fluid
viscosity η with the following expression:
rH =
8ηL
πR4
. (3.9)
Equation 3.9 can also be applied to rectangular channels, which is the case for most of
the microfluidic channels. An approximation can be used for high aspect ratio geometry (e.g
h/w≪ 1) and the hydraulic resistance can be approximated as:
rH =
12ηL
wh3
(3.10)
Combining equations 3.8 and 3.10, the pressure difference in a rectangular channel can
be estimated as:
∆p = Q
12ηL
wh3
(3.11)
Where η is the viscosity given in [Pa/s]. For a more precise approximation, a geometry
factor can be added to equation 3.11 and modified to:
∆p = Q
12ηL
wh3(1−0.630 hw)
(3.12)
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Equation 3.12 is valid only when h < w. This expression was used to estimate the length
of the inlets and outlets of the devices, in order to have a ∆p in the same order of magnitude
as the diffusion channel.
3.3.3 Final design and testing
Figure 3.8 shows a schematic of the IDS method and the two devices used in this study.
Multiple devices were tested but the preferred length was 10 cm and the difference is the
channel width. In the experiments described in Chapters 3 and 4, the detection of the
diffused and non-diffused fractions was performed in bulk after collection of the samples
in the outlets. For all the proteins, preliminary experiments were conducted with each of
the devices (Figure 3.8 b and d). Usually, a detected ratio smaller than 0.1 is in undesirable,
because below this value the slope of the curve becomes to steep, which means that a very
small change in detected ratio is a big change in size and this leads to large errors in the
measurements. The basis functions in Figure 3.8 c show that the 200 µm device run at 200
µ l/h is suitable for small particles of less than 6 nm radius. The 80 µm device (Figure 3.8 d)
is more suitable for larger particles, as it can be seen in the basis functions for this device
at a flow rate of 80 µl/h (Figure 3.8 e). When conducting experiments with proteins, an
experiment with the 80 µm device confirmed if the particle was large or small, since the
small particles were completely diffused at the end of the diffusion channel.
The height of the channels was measured with a profilometer and the exact height (usually
25± 5 µm) was adjusted in the basis functions for a more precise fitting of the hydrodynamic
radius. The flow rate at the outlets of the device was measured with Elveflow® flow sensors
to determine the volume ratio at the outlet of the channels. Figure 3.9 shows the calibration
curve of the flow rate measured against the one in the pumps. The graphics show the flow
rate measured at each of the outlets and the independent variable is the total flow controlled
by the nemesys pumps. The slope is the actual fraction of volume. We can see that the values
are not exactly 50:50, but with a small difference. The calibration was performed only once
and these values were adjusted in the the basis functions code, for a more precise fit value.
The calibration with the flow sensors also showed that a flow rate only stabilises after 6
minutes, and therefore for each of the experiments collection only started after 10 minutes of
selecting the flow rate with the nemesys pumps. This waiting time allows not only flow rate
stabilisation but also it allows the BSA (bovine serum albumin) present in the buffer to coat
all the PDMS channel and prevent non-specific binding of the target protein.
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Fig. 3.8 Final designs of the devices used for IDS. a) Schematic description of the Immuno Diffusional
Sizing method. The protein is injected into one inlet and buffer into the other at a flow rate ratio of
19:21. The streams meet at the junction and due to laminar flow they run side by side through the
channel. At the end of the diffusion channel the streams are split into two equal parts (50:50) and both
fractions ( fd and fnd) are collected separately for analysis. The diffused and non-diffused fractions
are analysed separately with a sandwich immunoassay in order to quantify the protein of interest. b)
The 200 µm width device is optimal to use for small particles, while c) the 80 µm width device is
optimal to use for larger particles. c) The basis functions for the 200 µm device at 200 µl/h, and e)
the basis functions for the 80 µm device at 80 µ l/h. The yellow area indicates the optimal size ranges
to avoid large errors when the slope ∆Rh∆Ratio becomes too steep or flat.
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Fig. 3.9 Flow rate calibration at the outlet channels. The slope of the graphic represents the variation
of the flow as a function of the inlet flow controlled with the pumps, which is the real fraction of the
outlets. a) Data and fitting of the 200 µm width device outlets and b) the 80 µm width device outlets.
The flow rate profile at the nozzle was tested with fluorescent colloids of 25 nm radius, as
shown in Figure 3.10. The images show that the flow in the beginning is well-defined so this
nozzle geometry is the preferred one, as it allows a faster equilibration and air bubbles are
eliminated easier. This test was also performed to observe the behaviour of the flow rate over
time, mainly because these experiments usually run for long periods of usually half an hour
up to even two hours, where it is important that the flow remains relatively stable. Figure 3.10
shows the change in the separation position of the two strems (fluorescent colloids and water)
over time. Over 70 minutes, the separation position of the 80 µm device is in average 38.08
± 0.25 µm, while the one of the 200 µm device is 95.6 ± 1.15 µm. But this fluctuation
should not affect the separation outlet, which is at 40 µm and 100 µm, designed like that
precisely to avoid the errors at the inlet. A final test with monomeric insulin was conducted
with the new device design (200 µm width at 400 µl/h) and the resulting size was 1.24 ±
0.22 nm which is in good agreement with the reported size of 1.3 nm [141].
In this project, some of the experiments with the prions (Chapter 4) were conducted
in a biosafety laboratory, therefore the method was optimised with conditions suitable to
work with infectious material and under a biosafety cabinet. But a possibility to reduce the
errors in the measurements would be by the use of a pressure-driven flow instead of the
syringe pumps, as the pressure driven system is typically more stable and the pumps cause
fluctuations in the flow [142].
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Fig. 3.10 Fluorescent images of the flow with pushing mode at 80 µ l/h at the 80 µm width channel a)
inlet and b) outlet of the 10 cm length device, and the 200 µm width channel c) inlet and d) outlet.
The sample in the protein channel are fluorescent colloids of 25 nm radius, run against mQ water.
Images were acquired every 5 min, and the fluctuations in the flow affect the separation position of the
streams. e) Flow stability at the nozzle of the 80 µm width device and f) the 200 µm width device.
3.4 Conclusions
During this project I have optimised the diffusion device design for its use with immunoassays.
The main changes resulted in a simpler geometry with the width and length optimised to work
with either small or large particles. The H-filter geometry allows the use of this device in a
label-free environment and smaller errors caused by fluctuations in the flow. Nevertheless,
this device has great potential to be coupled with other detection techniques that would
otherwise be difficult to adapt for on-chip detection, for example mass-spectrometry. The
fraction-collection makes it suitable to adapt to non-homogeneous immunoassays, such as
sandwich ELISA. The following Chapter describes the applications of the method presented
here for its use with prions and amyloidogenic oligomers.
Detection with fluorescently-labelled antibodies has great advantages over other tech-
niques. It provides great sensitivity and specificity. In order to reduce the errors related to the
time-dependency of the FRET signal, a standard curve was measured simultaneously with
the separated fractions. Furthermore, to avoid errors and false negatives of the “hook-effect”,
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the highest concentration of protein injected into the device was chosen to be the highest
possible in the standard curve, after which the FRET signal decreases. For biological samples,
it is recommended to make multiple serial dilutions of each of the fractions to avoid false
negatives when an excess analyte concentration is present.

Chapter 4
Size analysis of prion proteins and
amyloidogenic oligomers with IDS
The content of this Chapter is based on a manuscript in preparation for submission to Nature
Methods: “Direct Size Determination of Prions and Amyloidogenic Oligomers”.
This chapter is divided in two parts, the first one describes the application of IDS to prion
proteins, and the second one focuses on the application to amyloidogenic proteins.
4.1 Part I: The prion protein
Prion diseases or transmissible spongiform encephalopathies (TSEs) are a group of neurode-
generative disorders that belong to the Protein Misfolding Diseases (PMDs), with the main
difference of being infectious. While some people have claimed that proteins like Aβ in
Alzheimer’s disease and aSyn in Parkinson have prion-like properties, their infectivity has
not yet been demonstrated [143]. TSEs involve the accumulation of aggregated forms of
the prion protein (PrP). The term “prion”, derived from “protein + infection” was coined
by Stanley Prusiner in 1982, after isolating the minimal infectious unit that is required to
spread scrapie among sheep, and finding that is composed of PrP only [144]. PrP exists as
PrPC (cellular) in non-infected hosts, and as PrPSc (Scrapie) as the major component of the
scrapie infectious agent. The human forms of prion disease are Creuztfeldt-Jakob disease
(CJD), fatal familial insomnia (FFI), German-Straussler-Scheinker (GSS) syndrome, kuru
and variably protease sensitive prionopathy (VPSPr). They arise sporadically, genetically
or be acquired, with the latter accounting for only 5% of the cases of human prion disease
[145].
50 Size analysis of prion proteins and amyloidogenic oligomers with IDS
N-terminal domain
(unstructured)SP GPI
C-terminal domain
(globular)
23                                         120                                                  231        253Residue #:
Fig. 4.1 Schematic description of the structural domains of PrP. The protein, after transcription is 253
amino acids in length and includes a signal peptide (SP) that is cleaved and the 232-253 fragment is
replaced by a glycosyl anchor GPI (glycophosphatidylinositol). Adapted from [146].
4.1.1 The structure and function of PrP
PrP is a cell-surface mammalian protein synthesised in the central nervous system (CNS)
and various non-cerebral tissues, such as blood lymphocites, muscle, heart, kidney, and the
digestive tract [147]. PrP is encoded as a 253 amino acid protein, but the final processed
form contains amino acids 23-231. The peptide 1-22 is cleaved as a signal peptide and the
232-253 fragment is replaced by a glycosylphosphatidylinositol (GPI)-anchor [148]. Native
PrP is isolated as a mixture of unglycosylated, mono-glycosylated and with two glycosyl
groups. The “protein-only” hypothesis [149, 150] proposes that TSEs are caused by the
misfolding of PrPC into the scrapie form PrPSc.
The recombinant human PrP, hPrP 23-230, is formed by a globular domain and an
N-terminal disordered tail [101]. The globular domain contains a disordered loop, 3 alpha-
helices and a short anti-parallel beta-sheet. The disordered loop (167-171) is shared with the
murine PrP (mPrP). The small differences in the structure of PrP among different species
may provide insights for the species barrier of the infectivity.
The physiological function of PrPC is still unknown, but because its structure is highly
conserved in mammals it is thought that its role exerts beneficial functions [151]. To
understand its role, different controlled animal models were created and the first one were
knockout mice that lack the PrnP gene, Zurich 1 (or ZH1 PrnP0/0). However, no significant
abnormality was found except resistance to prion infection and a small alteration in behaviour.
A latter study showed that the PrnP knockout mice had deficiencies in memory and spatial
learning. Other possible functions suggested for PrP are its role in the regulation of sleep,
modulation of synaptic mechanisms and neuronal excitability, as well as a possible role in
embryonic development and as neuroprotector in acute cerebral ischemia and against aβ
oligomers toxicity.
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4.1.2 The structure of PrPSc
The protein-only hypothesis states that the transmissible agent of prion diseases is composed
of misfolded PrP only, and lacks nucleic acid [152]. The evidence shows that the infec-
tious agent is resistant to UV and ionizing radiation, which normally destroy nucleic acids.
However, the ultimate proof for this hypothesis, i.e. the generation of PrPSc in vitro, is still
missing. Originally the term PrPSc was directly related to the protease resistant fraction, as
infectivity as well as concentration are dependent on digestion conditions. The isolation of
the protease-resistant form (PrPres) which copurifies with infectivity, is perhaps the strongest
evidence that supports the prion-only hypothesis. The virino hypothesis is one of the alter-
natives to the prion-only, and suggests that the transmissible agent is a small informational
molecule encapsulated on a tight protein coat [153]. But this hypothesis is not really widely
accepted. The main problem to address the prion problem is that the precise structure of the
transmissible prion is not yet completely known. The main challenge to resolve the complete
structure is the difficulty to maintain PrPSc infectivity throughout purification. Another
challenge is the lack of solubility of the PrP aggregates, which makes it difficult to study
with NMR or X-Ray crystallography.
Unlike PrPC, PrPSc is characterised by a high beta-sheet content. Electron cryomicroscopy
(cryo-EM) has provided insights into the structure of brain-derived GPI-anchorless PrPSc
[154]. The structure of infectious prion from mice expressing GPI-anchorless PrP shows
a four-rung β -solenoid as its key feature, and fibril segments with a repeating unit of 1.91
nm. Micro electron diffraction (MicroED), a cryo-EM method, reveals a bank vole prion
protofibril with amyloid-like features [74]. MicroED shows that a 3D network of hydrogen
bonds and stacked aromatic residues stabilise the structure of proto-PrPSc.
4.1.3 Prion protein antibodies
The Aguzzi lab (Institute of Neuropathology,University of Zürich, Switzerland) has created
a variety of antibodies specific for different epitopes of PrPC [104] by immunisation of
PrnP0/0 knockout mice with recombinant mPrP. The monoclonal antibodies, named POM1 to
POM19, are specific to several epitopes of PrPC, including the N-terminal region, as shown
in Figure 4.2.
Although the development of prion antibodies emerged as a possible therapeutic against
prion diseases, studies with the POM antibodies have shown that the antibodies that bind to
the globular domain of PrP induce neurotoxicity [155]. This suggested that the flexible tail
transmits the toxic signals that trigger oxidative stress and calpain activation.
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Fig. 4.2 POM antibodies and their binding sites to PrP(23-230). The antibodies selected for these
studies were POM1 and POM19. Reproduced from [155].
4.2 Results and discussion
All prion experiments were performed in the Institute of Neuropathology, University of
Zürich. The experiments involving Rocky Mountain Laboratory strain mouse-adapted
scrapie prions (RML-infected) brains were performed in biosafety laboratories at level 2 or 3.
4.2.1 Selection of the FRET antibody pair
The application of IDS to the study of prions would have not been possible without an
adequate FRET antibody pair suitable for PrPC. The selection of the FRET labelled pair
was conducted by testing four different combinations of FRET-labelled POM antibodies and
choosing the one with the highest FRET signal and better dynamic range. Figure 4.3 shows
the standard curves for the FRET pairs tested. The fitting of the data was performed with
a sigmoidal 4-parameter logistic (4PL) equation, and the points after the hook point were
eliminated. The FRET pair of APC-POM1/Eu-POM19 was selected as its shows the highest
signal of the pairs, and it has also the broadest dynamic range of all the pairs.
4.2.2 Sizing of the recombinant mPrP
The first step in this project was to test the device with the recombinant monomeric PrPC to
measure its size and ensure that the device was suitable to work with this protein. In order to
prevent PrPC aggregation due to the presence of salt, the first experiments on the microfluidic
device were performed with PrPC in mQ water. In water the protein was sticking in the
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Fig. 4.3 Net FRET signal against PrPC concentration for the different antibody pairs tested, a)APC-
POM1/Eu-POM2, b)APC-POM1/Eu-POM19, c)APC-POM3/Eu-POM1 and d)APC-POM3/Eu-ScFv-
POM1. e) Comparison of the standard curves for all the FRET-labelled POM antibody pairs tested.
plastic syringe and in the PDMS device. A successful experiment was performed with tris
buffer and BSA (see Methods, Chapter 2, Section 2.3), since BSA adsorbs to the channel and
prevents PrP sticking to the channels. The size of recombinant mPrP was then measured at a
concentration as low as 100 nM and obtained a radius of 2.73 ± 0.5 nm, which is in good
agreement with the 3.1 ± 0.5 nm value obtained at 300 µM with DLS and indicating that the
mPrP is monomeric under the conditions tested. We note that the slight difference in size
may be due to the change in viscosity caused by the variation in concentrations used in the
two techniques.
54 Size analysis of prion proteins and amyloidogenic oligomers with IDS
Zurich 1
PrP0/0
Tg20 
RML-infected
Tg20
1% BH
spiked 
monomer
1% BH
PrPres1% BH
PrPC and PrPSc
1) PK-digestion
2) PMSF
b
c
d e
PrPC and PrPSc
Homogenate
PrPC
Homogenate
 PrPC monomers No PrP
C
expression
Homogenate
mPrP
recombinant
a
Fig. 4.4 a) As a control experiment the recombinant PrPC was measured at a concentration of 20
nM in buffer only. b) Recombinant PrPC was spiked into knockout BH, of ZH1 PrP0/0 mice, also at
a concentration of 20 nM. c) PrPC overexpressing mouse (Tg20) BH was directly injected into the
device and its size (3.1 nm) quantified via IDS. BH of RML-infected Tg20 contains both PrPC and the
scrapie isoform PrPSc. d) We have injected this BH directly into the device, and e) after digestion with
proteinase-K (PK) enzyme followed by the addition of protease inhibitor phenylmethane sulfonyl
(PMSF) to stop digestion before injection into the device. In this way the only species we detect with
the TR-FRET are the PK-resistant ones.
4.2.3 Sizing of brain mPrP
The study of the native state of PrP from brain tissue is important for understanding its
pathological effects, as it could provide a potential explanation for why it is prone to
pathological aggregation. To investigate the difference between recombinant PrP and brain
PrP in Tg20 mouse brain homogenate, we first “spiked” the recombinant form into Zürich 1
double knockout (ZH1 Prnp0/0) brain homogenate (BH) and injected the BH directly into the
microfluidic device (Figure 4.4 b). The obtained size of 3.5 ± 0.5 nm suggests no significant
change in size from the pure recombinant mPrP. Then we investigated the size of protein
directly obtained from PrPC overexpressing mice (Tg20) BH (Figure 4.4 c), and compared
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Fig. 4.5 The hydrodynamic radii of the different prion experiments made in this study. Values in
bar graph represent mean ± SD of n = 3 experiments performed with different devices. One-way
ANOVA P < 0.0001, followed by Tukey’s HSD test ∗∗∗∗P < 0.0001.
this to the one on RML-infected Tg20 BH of mice at the terminal stage of prion disease
(Figure 4.4 d). Surprisingly, a similar size to the monomer (3.1 nm) was obtained in both
cases (Figure 4.5). This could be explained because the fibrillar form of PrPSc is at much
lower concentrations than the native PrPC and therefore we mainly measured the size for
the most abundant form, PrPC. The method presented here provides information on the
average radius of all the species in solution that the antibody pair binds to, and if that includes
monomers and oligomers the results will be biased towards the higher concentration species.
4.2.4 Size of PrPres in mouse brain homogenate.
One of the drawbacks of this study was the lack of a FRET antibody pair that binds only to PrP
aggregates, since the POM antibodies bind only to PrPC epitopes. In order to overcome this
limitation and to size the misfolded, protease-resistant prion protein (PrPres), we have treated
BH of RML-infected Tg20 mice at the terminal stage of prion disease with proteinase-K (PK)
digestion followed by addition of phenylmethyl sulfonyl (PMSF) to stop the digestion (Figure
4.4 e), before injection into the microfluidic device. Different conditions of PK-concentration
and incubation times were tested in order to remove most of the monomeric PrPC without
digesting all the PrPres fraction. In this way we guaranteed that the only PrP species in
solution are PrPres aggregates. However, by treating the sample with PK around 90% of PrP
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was digested and the concentration was too low to be detected with TR-FRET, necessitating
detection with a sandwich ELISA to detect down to subpicomolar concentrations. The
complete removal of PrPC and the presence of PrPres after PK-digestion was confirmed with
Western Blot analysis (See Appendix A Figure A.1). As shown in Figure 4.5, we obtained
a size of 86.5 nm in a range from 77.7 to 97.1 nm, which indicates the average size for the
PK-resistant aggregates found in the infectious brains.
4.3 Conclusions of PrP experiments
The application of IDS to the study of prions has demonstrated it has great potential for the
study of native and infectious proteins at the biologically relevant conditions. The purification
of prions represents a major challenge as parts of prion infectivity are lost during the PK-
digestion process, and this method has overcome this limitation by measuring the sample
directly without purification.
I have demonstrated the ability of this system to resolve a complex mixture such as mice
brain homogenates, with monomeric and aggregated samples. Furthermore, characterising
the average size of the prion in a biological fluid could potentially work as a diagnostic tool,
as these data indicate that PrP aggregation can be detected when the average hydrodynamic
radius exceeds the size of monomeric PrPC.
4.4 Further work
A final piece of further work that would be useful is one that would address one of the
limitations of IDS - the fact that it relies on a FRET antibody pair for detection. The size of
the relevant infectious particles, PrPSc, in BH undigested sample would be possible with a
TR-FRET pair specific for PrPSc.
We have used only one FRET antibody pair for all experiments, as this pair is suitable to
work with BH. However, in order to be safe and make sure that all the infectious relevant
species are measured, tests with different POM antibodies should be performed to confirm
the current results.
In order to obtain more information from the infectious particles, the separated fractions
of IDS could be tested for infectivity. Measuring the infectivity of both fractions would allow
the clarification of which of the smaller or larger particles are the most infectious agents.
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Fig. 4.6 The schematic shows the APP domains and the cleavage sites that lead to the formation of
the amyloid β peptide. Adapted from [159] and [158].
4.5 Part II: Amyloidogenic oligomers
Amyloid-oligomers are increasingly thought to be the main cytotoxic agents in many neu-
rodegenerative diseases, such as Alzheimer’s and Parkinson’s disease. Size could be a
determining factor of the activity of oligomers as smaller species may diffuse faster and have
a larger number of growing ends per unit mass of peptide [156].
4.5.1 Amyloid β properties
Amyloid Precursor Protein (APP) is a member of the APP family, which is conserved across a
variety of species from mammals to invertebrates [157]. The function of APP has been widely
studied due to its association with Alzheimer’s disease (AD) and it has been suggested that
it plays a key role in neuronal signaling, which may explain why APP disruption may lead
to neuronal damage. APP has other key physiological functions during brain development
and in neuronal plasticity, memory and neuroprotection in the aging brain [158]. Although
the complete X-Ray structure of APP has not been resolved yet, it is available for the folded
E1 and E2 subdomains, and information from NMR solved the structure for the C-terminal
fragment-β and the cytoplasmic tail. Figure 4.6 shows a schematic description of the APP
domains.
Monomeric Aβ is produced from the APP via cleavage by the enzymes β - and γ-
secretase. The cleavage sites are indicated with arrows in Figure 4.6. The cleavage of
γ-secretase occurs at various positions, leading to the formation of peptides of different
lengths, such as Aβ43, Aβ42, Aβ40, Aβ38, and Aβ37 [52]. The Aβ42 peptide in particular,
has received more attention as it has been considered to be the major etiologic agent due to
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its more aggressive aggregation properties [160]. Aβ monomer is mostly unstructured in
aqueous solutions, representing a equilibrium of interconverting conformations rather than a
unique fold, determined by the solution conditions [161].
The amyloid cascade hypothesis suggests that the main pathological agent in Alzheimer’s
disease is the deposition of Aβ [162]. The hypothesis suggests that the tangles, neuronal
damage and dementia are an effect of the peptide deposition, but it also suggests that other
causes may trigger Aβ deposition, for example head trauma or mutations in the APP gene.
However, in the last fifteen years the hypothesis has been modified with focus on the soluble
oligomers as the most toxic species [163].
Unfortunately, due to their transient nature and high heterogenicity, the low-molecular
weight oligomers are difficult to analyse with high resolution techniques [52]. Moreover,
oligomers of a specific structure are difficult to isolate and therefore it has not been possible
to obtain a high-resolution structure for the oligomeric species of Aβ40 and Aβ42 [164].
But even low-resolution techniques present some difficulties in studying these aggregates.
DLS for example, would not only be biased towards the larger species in a heterogeneous
mixture, but also would need a relatively high concentration of sample [87]. Therefore,
the term oligomer has been broadly used to describe some form of non-fibrillar aggregates
[165] such as disordered aggregates, micelles, protofibrils, prefibrillar oligomers and anular
protofibrils. While the precise definition of an “oligomer" is broad, they can be classified by
their origin in ‘ex vivo" or brain-derived oligomers and “in vitro-generated oligomers" [52].
The preparation method and solution conditions affect the structure of in vitro-generated
oligomers, such as the buffer, ionic strength and metal ions. The latter are of particular
interest since they have demonstrated to alter the kinetic pathway of Aβ aggregation as well
as the structure of the aggregated species. Heavy metal ions are the first suspected to be
implicated in the pathology of Alzheimer’s disease due to their neurotoxic activity, but recent
evidence points to the biologically important metals such as Zn, Cu and Fe [166, 167]. Some
studies also focus in non-physiological aluminium, due to its prevalence in our environment
[168].
The Zn2+ ion has been shown to inhibit the aggregation of Aβ at substoichiometric
concentrations, by formation of a Aβ40-Zn2+ which binds to the fibril ends and reduces the
elongation rate [169]. The interaction of Aβ and copper is stronger than that of Aβ -Zn, and
some studies suggest then that the complex Aβ -Cu may play an important role in the early
stages of Aβ aggregation [170]. The role of Aluminium in Alzheimer’s disease remains
controversial, mostly because it has been shown to be neurotoxic, but it seems to be poorly
absorbed and efficiently excreted from the body [171]. Iron, along with Zinc and Copper,
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has been found colocalised with Aβ aggregates in senile plaques [172]. Iron has been shown
to increase Aβ generation and oligomerisation due to its chelating properties, like zinc and
copper, which may form complexes with the His and Tyr residues located at the hydrophilic
N-terminal region of the peptide [173].
4.5.2 aSyn properties
Synucleins are a group of proteins predominantly expressed in the brain, whose function
is not yet totally understood. The synuclein family is formed of α-Synuclein (aSyn) and
the β and γ isoforms, with 127-140 aminoacids in length (≈ 40 kDa) and 50% similarity
in sequence [174]. The protein sequence was first described in 1988 and named after
its association with the synaptic vesicles and nuclear envelopes. aSyn is an intrinsically
disordered protein, capable to adapt a variety of conformations, whose features depend on
the protein environment and interactions with other binding partners [175]. The aSyn domain
structure and sequence are depicted in Figure 4.7. It is mostly known by its association
with multiple neurodegenerative disorders, like Parkinson’s disease (PD) and the major
non-amyloid beta component (NAC) of the amyloid plaques found in Alzheimer’s disease
patients [176].
The association of aSyn with PD was discovered as it was found to be the major com-
ponent in the 70 molecules identified in Lewy Bodies (LBs), which are protein aggregates
that are the pathological hallmark of the disease [177]. The direct role of aSyn in PD was
demonstrated by genetic evidence, as a series of familial mutations leading to early-onset
(A30P, E46K, A53T, G51D) or late onset (H50Q) PD have been shown to dramatically affect
the rate of fibril production in vitro [178]. In addition to genetic modifications, it has been
shown that post-translational modifications (PTMs), such as phosphorylation, nitration and
dopamine modification to aSyn, could alter its propensity to aggregate or form oligomers
[179]. Ubiquitination at multiple sites has also been found in CSF samples of PD patients but
also in control samples [180]. The role of ubiquitination in PD is not completely understood.
Whereas polyubiquitinated proteins are targeted for degradation by the proteasome system,
monoubiquitinated proteins are not, and interestingly only the mono and diubiquitinated
aSyn are the main forms found in Lewy bodies [181].
The general mechanism of aSyn aggregation has not been totally described yet. Recent
evidence shows that aSyn aggregates proliferate by a prion-like process of protein seeding
[182]. Moreover, it has been shown that the aggregation of aSyn depends strongly on
the solution conditions. For example, at mildly acidic pH the amplification of aggregates
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Fig. 4.7 The schematic shows the aSyn domain structure and amino-acid sequence, as well as the
point human mutations indicated in red. The N-terminal domain folds into two helices upon binding
to lipid membranes. Helix 2 contains the non-amyloid β component (NAC) domain (residues 60-95),
which is prone to aggregation. Adapted from [176] and [174].
via secondary nucleation of monomers on the surface of fibrils, is much faster than at
physiological pH [183]. Other studies suggest that the interactions of aSyn with lipid
membranes play a key role in the aggregation process, as the presence of small unilamellar
vesicles (SUVs) enhances the primary nucleation rate of aSyn by three orders of magnitude
or higher [184].
The small oligomers formed during the aggregation process are thought to be the most
cytotoxic species. By isolating stable aSyn oligomers their toxicity was shown by measuring
their ability to disrupt lipid membranes and generate reactive oxygen species (ROS) in
primary neuronal cells [108]. Moreover, solid state NMR experiments demonstrated that the
main structural elements that give rise to oligomer neurotoxicity are the highly lipophilic
element of aSyn oligomers that interacts strongly with the membranes, as well as a structured
region that is able to disrupt them [185, 186].
The native state of aSyn is also important to understand its role in neurodegenerative
disease. The pathological end-state of PD is well described from post-mortem tissue, but the
early stage of the disease remains unclear. Whilst recombinant aSyn is largely unfolded, some
studies propose that native brain aSyn purified from erythrocytes forms a stable tetramer that
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prevents aggregation [187]. Other studies show that endogenous aSyn, purified from mice
brain tissue, consists of an unstructured monomer and is aggregation-prone [188].
In this chapter, a combination of microfluidics with immunoassays, TR-FRET and
alphaLISA , provide insights on the structure of stable aSyn oligomers as well as brain aSyn
present in transgenic mice SNCA-OVX brain homogenates that express wild-type (WT)
human aSyn at disease relevant levels [189].
4.6 Aims
The aim of these studies is to determine the hydrodynamic radius of two intrinsically
disordered proteins, the Aβ40 peptide and aSyn in their monomeric and oligomeric forms.
The Aβ40 peptide in particular has been challenging to study in a label-free manner, mainly
because it does not have any tyrosines or tryptophans it its structure which would allow the
study with intrinsic fluorescence. Due to their heterogeneous nature, any given isolation
procedure could select a certain population of oligomers that might not reflect the spectrum of
oligomers that exist under biologically relevant conditions. Moreover, since most biophysical
studies are typically performed at non-physiological high-micromolar concentrations, it has
not been possible to extrapolate the observations to very low total concentrations of oligomers
observed in vivo. IDS could provide an alternative as it measures the hydrodynamic radius in
a very sensitive way, and the method could apply for different solution conditions, such as
different buffers and ionic strength background.
4.7 Results and discussion of amyloidogenic oligomers
Size of the Aβ40 monomer and metal-stabilised oligomers
IDS was suitable to characterise the size of the intrinsically disordered peptide, Aβ40, and
its metal-stabilised oligomers at a concentration of 2 nM, as shown in Figure 4.8. The
hydrodynamic radius of the monomer (0.9 ± 0.1 nm) is in good agreement with fluorescent
correlation spectroscopy (FCS) (0.9 ± 0.05 nm) [190]. But it seems to be slightly smaller
than the size obtained with NMR of 1.59 ± 0.1 nm at 25 ◦C [191]. The difference in the size
obtained could be due the errors in dilutions caused by the low concentration needed in IDS
of 2 nM.
The IDS method proved very useful in sizing the oligomeric forms of Aβ40, since
these oligomers should be prepared in tris buffer, as any saline buffer like phosphate would
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Fig. 4.8 Size of Aβ40 monomer and oligomers. The sizes were measured with IDS at concentrations
of 2 nM in tris buffer with 0.01% tween to prevent stickiness. Values in bar graph represent mean ±
SD of n = 3 experiments performed with different devices. One-way ANOVA P = 0.0297, followed
by Tukey’s HSD test ∗P < 0.03.
cause the precipitation of metallic ions. The presence of tris prevents the measurements
being performed with the Nu-sizing method [112] due to the presence of amines in the
buffer. The main advantage of IDS over traditional sizing techniques such as DLS, is the
low concentration needed to make the measurements. The sizing of the oligomers with
DLS shows a bigger size because the hydrophobic surface of the oligomers makes them
form clusters at the mili or micromolar concentrations needed for DLS. The measurements
conducted at 2 nM guarantees that the measurement is made for oligomers rather than for
clusters.
4.7.1 On-pathway oligomers
A key experiment to exploit in this method would be the sizing of on-pathway Aβ40
oligomers. The main drawback of this experiment was the lack of an antibody pair specific
for aggregated forms of Aβ . Since the TR-FRET pair used to detect Aβ40 binds to its
monomer as well as oligomeric forms, size exclusion chromatography (SEC) was used
to separate the predominant monomeric fraction from the on-pathway oligomers of an
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Fig. 4.9 Schematic description of the on-pathway oligomers experiment. a) Aggregation curve of
Aβ40 (60 µM) at 37 ◦C, the error bars represent the standard deviation of three curves. The sample
collection was conducted after 1.6 h reaction before separation with SEC. b) The chromatogram
shows the monomer and collected fractions (F1, F2 and F3) which should correspond to the oligomers.
c) The calculated sizes of monomer, F2 and F3 obtained with IDS, while the F1 concentration was
below of the limit of detection of the TR-FRET. Values in bar graph represent mean ± SD of n = 3
experiments performed with different devices. One-way ANOVA P = ns.
aggregation reaction. Without the separation of the monomer, the result of IDS would only
be the size of the monomer as it is the highest concentration species and the provided size is
an average of all the species in solution.
As shown in in Figure 4.9 a, the sample was collected at 1.6 h which corresponds to the
half time of the aggregation reaction. This time was chosen as previous simulations show that
around this time the population of oligomers peaks [192]. Figure 4.9 b shows the fractions
selected, F1, F2 and F3, that elute just before the fraction of the monomer. The resulting
hydrodynamic radius (Figure 4.9 c) for the F2 and F3 of 1.00 ± 0.13 nm and 1.16 ± 0.16
nm respectively, are not too different of the size that corresponds to the monomer, of 0.9 ±
0.1 nm. The size of F3 could not be estimated with IDS as the concentration of this fraction
was below the limit of detection of the TR-FRET assay. The measurements could not be
compared to other sizing methods, like DLS, due to the low concentration of F2 and F3, of
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1-2 nM. The hydrodynamic radius of F2 and F3 could only be the ones of the monomer, since
these oligomers are metastable and it is possible that they have dissociated during the SEC
separation. However, it is also possible that the sizes of the oligomers are just small, like the
case of the stabilised Zn2+ and Al3+ oligomers, whose sizes are quite close to the monomer
radius.
A key experiment would be performing the experiment directly after aggregation without
any separation, but this requires an antibody pair which detects the soluble oligomers only,
not the monomer or the fibrils. The detection with such a pair, would also make it possible
to study the size of oligomers present in CSF of Alzheimer’s disease patients, which due to
their low concentration in the subnanomolar range, would make it impossible to study their
sizes [193].
4.7.2 Size of aSyn monomer and oligomers
We exploit the sensitivity of the method to characterise disordered structures, such as the aSyn
monomer to the size of a relevant Parkinson’s complex, the stabilised aSyn oligomers (8 ± 1
nm) [108] (Figure 4.10). The sizing of the oligomers was performed with the microfluidic
device designed for large particles, and the detection was conducted with a TR-FRET pair
specific for aggregated aSyn, since it is a monoclonal antibody specific for aggregated
aSyn labelled with either donor or acceptor, and then produces a FRET signal only in the
presence of aggregated forms. In the case of the monomer, the detection was performed with
alphaLISA immunoassay, at a picomolar concentration (233 pM), as the signal depends on a
chemiluminiscence reaction upon proximity of the two antibodies. The estimated size for the
monomer (2.3 ± 0.8 nm) corresponds well with previously reported size (2.82 nm) [194].
4.7.3 Size of brain aSyn
The native state of brain aSyn has been a subject of discussion as some studies suggest that
it consists of a largely unfolded monomer that is prone to aggregation [188] while others
suggest it is well structured tetramer that resists aggregation [187]. The discrepancy may
be due to the purification method of brain aSyn on each of the studies. IDS provides the
possibility to study the hydrodynamic radius of brain aSyn without purification. In this study,
aSyn-overexpressing (SNCA-OVX) brain homogenate (BH) was used at 0.01% and injected
into the microfluidic device (Figure 4.11 a). In order to determine the possible presence of
aggregates, the sample was first tested with the TR-FRET pair for aggregated aSyn, but no
signal was observed. A control of wild-type mouse BH was also tested in order to determine
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Fig. 4.10 Size of aSyn monomer and oligomers. The size of the monomer was measured with IDS at
concentrations of 233 pM in tris buffer. The oligomers were measured at a concentration of 47 nm
(in mass equivalents). Values in bar graph represent mean ± SD of n = 3 experiments performed
with different devices. One-way ANOVA P = 0.0024, followed by Tukey’s HSD test ∗P < 0.03,
∗∗P < 0.002.
if the centrifugation steps induce aggregation, but the TR-FRET pair was binding poorly to
murine aSyn as a control experiment with recombinant murine protein showed. Therefore
the following experiments were conducted with an alphaLISA assay specific for monomeric
aSyn and the results, shown in Figure 4.11 b), indicate no significant difference between
the size of the recombinant monomer (2.3 ± 0.8 nm) and the brain aSyn (3.34 ± 0.8 nm)
measured at 233 pM and 0.01% BH, respectively. For comparison purposes, the recombinant
aSyn was also measured with the benchtop unit of the native diffusional-sizing method [112]
but in PBS since this unit utilises OPA labelling which binds to free-amines and therefore
would bind to the tris-buffer. The result of 3.7 ± 0.1 nm is in good agreement with the size
of the brain aSyn. Even though the recombinant protein seems to be smaller, the literature
actually reports different values for the size of monomeric aSyn which range from to 2.0 to
2.96 ± 0.36 nm [112]. aSyn is an intrinsically disordered protein whose conformation state
may vary depending on the solution conditions and temperature.
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4.7.4 Post-translational modifications of aSyn
IDS depends on the detection of proteins with antibodies specific for them. Therefore if the
method is applied to measure a biological sample or body fluids, a number of things are
unknown, such as the concentration and the state of the protein, like the possible presence of
post-translational modifications (PTMs), for example. A measurement of his-tagged aSyn
was performed and compared to the same sample after in vitro translation (IVT) and in
vitro ubiquitination IVU. As depicted in Figure 4.11 c, the IVU reaction performed with an
enzyme is supposed to stop after 1 h, but this sample was measured after overnight incubation.
A possibility is that the large protein size after the IVU reaction compared to the IVT of
3.5 ± 0.3 nm (Figure 4.11 d) is due to the presence of multiple ubiquitins bound to the
protein. Furthermore, it was unclear whether the antibodies used in the alphaLISA assay
would detect post-translationally modified (ubiquitinated) aSyn with the same sensitivity
as with the detection of unmodified aSyn. If the sample was a mixture of mono, di and
poly ubiquitinated aSyn, the diffused-fraction may contain species that cannot bind to the
antibodies and the signal of this fraction would be small, reflecting in a large size (22.8 ± 1.4
nm). In order to improve this measurement, an experiment with antibodies for the his-tag or
antibodies for ubiquitin rather than for aSyn would be the adequate to target the ubiquitinated
protein.
4.8 Conclusions
The IDS method was suitable to study amyloidogenic oligomers under biologically rele-
vant conditions. The experiments performed in this study were conducted with synthetic
oligomers but it has demonstrated the potential of IDS to study biological mixtures, like brain
homogenates. This method could potentially determine the protein sizes in biological fluids,
such as CSF, to provide insights into the oligomeric population at different stages of the
disease. Its main limitation is the requirement of an antibody pair specific for the aggregated
forms of the protein, because usually the oligomers are in low abundance with respect to the
monomer fraction. With a specific pair, a pre-separation step would not be necessary and the
measurement could be performed directly in a complex sample. However, these antibodies
are normally prepared by using synthetic oligomers as an immunogen, but the properties of
the oligomers vary depending on the protocol of preparation, and therefore, it is very likely
that any oligomer-specific antibodies obtained using a specific oligomer preparation may
detect only a subset of oligomers in vivo. In order to have a more reliable study, it would be
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good to perform the sizing with multiple antibody pairs. This method provides the sizes of
intrinsically disordered proteins and protein complexes in a biologically relevant state, in a
label-free manner and has overcome the sensitivity issues of traditional sizing techniques.
The study of PTMs could be an interesting application of IDS, with a suitable antibody pair
that targets a specific group such as ubiquitin. These antibodies are widely present in the
market and their use expands the application of IDS which is often limited by the need of an
antibody-pair specific for the target protein.
68 Size analysis of prion proteins and amyloidogenic oligomers with IDS
Diffusion
channelBuffer
alphaLISA
detection
0.01% BH
Homogenate
OVX
mice brain
Injection
to device
aSyn
a
IVT
E3 ligase 
aSyn specific  
1 h 37ºC
8 h 4ºC  
IVU
b
c
d
IVT IVU
0
5
10
15
20
25
30
R
H
(n
m
)
Recombinant
aSyn
Brain
aSyn
Recombinant
aSyn
Fluidity One
0
1
2
3
4
5
R
H
(n
m
)
***
Fig. 4.11 Schematic description of experiments with brain aSyn and PTMs. a) OVX BH at 0.01% was
injected into the microfluidic device to study the native state of aSyn. b) The resulting size of aSyn
in the BH compared to the size of the recombinant monomer measured with IDS at concentrations
of 233 pM in tris buffer and measured with the fluidity one at 100µM in PBS buffer. Values in
bar graph represent mean ± SD of n = 3 experiments performed with different devices. One-way
ANOVA P = ns. c) His-tagged aSyn was expressed in cell-free environment (IVT) and mixed with
E3 ligase enzyme for ubiquitination (IVU). d) The difference in size of IVT and IVU measured with
IDS. Values in bar graph represent mean ± SD of n = 3 experiments performed with different devices.
T-test ∗∗∗P = 0.0006.
Chapter 5
Towards TR-FRET on-chip detection
5.1 Introduction
Lab-on-a-chip immunoassays have greatly developed over the last two decades, leading
to a range of diverse biosensor concepts and applications [195]. The miniaturisation of
immunoassays into microfluidic technology represent many advantages such as the reduction
of reagent consumption, portability, lower cost of the assay and a controlled environment
[196]. However, the reductions in scale may result in a number of challenges such as the
requirement of extremely sensitive detection schemes. This may be overcome by enhanced
amplification, which is usually achieved by multiple steps assays, difficult to perform on-chip.
An alternative could be the use of an homogeneous (in-solution) time-resolved FRET (TR-
FRET) immunoassay, a fluorescence-based technique which has a wide range of applications
from protein folding and dynamics to biosensing microfluidic reactors [197]. TR-FRET
offers great analytical sensitivity and does not require antibody immobilisation. On the
other hand, it remains challenging to miniaturise, partially because of the low quantum yield
produced by the TR-FRET signal.
5.1.1 The principles of FRET
Föster resonance energy transfer (FRET) is a phenomenon widely utilised in biophysical
research of macromolecular interactions due to its high resolution of typically 0.1 nm. FRET
is a process in which a donor molecule in its excited state transfers its excitation energy
through dipole-dipole coupling to an acceptor fluorophore, when both species are in close
proximity (typically 1 to 10 nm) [198]. Although IUPAC nomenclature is Föster resonance
energy transfer, sometimes it is also referred to as fluorescence resonance energy transfer.
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FRET is a two-step process that occurs simultaneously via a non-radiative process.
Excitation of the photons occurs from the ground (D) to the excited state (D*), and then the
acceptor is excited from A to A* via dipolar coupling between dipolar moments of the donor
emission and acceptor excitation [199]. FRET efficiency (EFRET ) varies as the sixth power
of the distance (R) between D and A and can be determined with the following equation:
EFRET =
R60
R60 +R
6
. (5.1)
where R0, Föster radius or critical distance, is the distance where FRET efficiency is
50% [134]. Although D-A proximity is necessary for FRET, orientation is also important. A
geometrical factor, κ2 , is related to R and it may change as R changes in different donor-
acceptor configurations [200]. κ is related to R as indicated with the following equation
(5.2):
R60 = 8.785×10−5
κ2ΦDJ
ψ4
(5.2)
where ΦD is the quantum yield of the donor in the absence of the acceptor, η is the index
of refraction (normally taken as 1.4 in aqueous solution), J is the overlap integral between
the donor and acceptor, of the peak-normalised fluorescence spectrum between the donor
and the acceptor [201].
Choosing a suitable donor-acceptor pair is a key step to perform a successful measurement.
Among the conditions they should meet are: a) Sufficient separation in excitation spectra
so that the light source is selective for the donor; b) enough overlap between the emission
spectrum of the donor and the excitation spectrum of the acceptor to ensure efficient energy
transfer; c) an adequate separation between the emission spectra to allow selective detection
of emitted fluorescence from the acceptor and d) the distance between both donor and
acceptor, when attached to biomolecules should be within 10 Å-100 Å [202].
5.1.2 alphaLISA as an alternative to TR-FRET
Since the FRET efficiency varies as the sixth power of the distance (eq. 5.1), the binding
distance detection of TR-FRET is limited to 9 nm [133], amplified luminiscent proximity
homogeneous assay (alphaScreen or alphaLISA) technology may represent an alternative to
TR-FRET. alphaScreen is an homogeneous, nonradioactive bead-based assay that utilises a
sandwich antibody pair. Described in 1994 by Ullman et al. [203], the method is based on the
channeling of singlet oxygen species, generated from a photo excitable latex bead with laser
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irradiation at 680 nm, to a second one located in close proximity to induce a chemiluminescent
signal [204]. The beads are covalently bound to the antibodies, and therefore they come in
close proximity in the presence of an antigen. The low background signal of the assay is due
to the short singlet oxygen lifetime (4 ms) and the maximum distance that it can diffuse (up
to 200 nm), as the beads are normally added in low concentrations to prevent non-specific
interactions. Thus, the detection binding distance of the assay is of 200 nm.
alphaScreen technology has been implemented to microfluidics [205]. In that study, the
detection mode was made by imaging several detection chambers simultaneously, as the
device also integrated microvalves and micropumps to control the injection of the multiple
reagents (antigent, antibodies and beads) at different times. Due to the complexity of the
device design, a one-step immunoassay like TR-FRET may be the preferred one to integrate
with IDS.
5.2 Aims of this project
In this project I have tried to implement the detection of TR-FRET at the microscale. Even
though a number of optic systems are suitable for single-molecule FRET [206, 207], the
detection of TR-FRET immunoassays on-chip remains a challenge. I have tested a custom-
built setup analogous to the plate reader, with a LED as an excitation source and a camera
for detection. I have also tested the detection with a photomultiplier tube (PMT) to obtain
suitable detection, with no success.
I have also made a comparison of the performance of the alphaLISA and TR-FRET
assays for the detection of insulin. Critical parameters for an assay include the sensitivity
and reproducibility. Furthermore, a limiting factor for the implementation of these assays
on-chip is the time required to get a stable signal. Therefore we have tested modifications to
the PerkinElmer protocol which affect the kinetics and equilibrium of the antibody-antigen
binding, such as incubation time, steps of addition, antibody concentration and temperature.
5.3 Results and discussion
5.3.1 Comparison of alphaLISA protocols
The protocol suggested by PerkinElmer involves a two-step one, which means mixing the
sample with the antibodies/-acceptor beads mix, incubating, incubating and adding the donor
beads for final incubation and reading. Although this protocol allows a better sensitivity, if
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Fig. 5.1 The sensitivity of the protocol decreases by adding all the reagents in 1 step. The total
incubation time for both protocols is 90 min. at 25◦C.
one would like to implement this technology for IDS detection, a multi-step protocol would
not be suitable for the reading on-chip. Therefore I measured the limit of detection (LDL)
and lower limit of quantification (LLOQ) for each protocol in order to estimate the sensitivity
loss by performing the assay in one step. Figure 5.1 shows the resulting standard curves
with each of the protocols, at the same total incubation time. For the two-step protocol, the
LDL was 7.94 pg/ml and the LLOQ was 23.44 pg/ml. The one-step protocol with a LDL of
82.00 pg/ml and LLOQ of 191.62 pg/ml was estimated. These values indicate a decrease in
sensitivity of roughly 10 times for the 1-step protocol.
Another drawback to the implementation of immunoassays on-chip could be the incuba-
tion time required to stabilise the signal. The signal stabilisation time depends on the kinetics
of the binding of antigen and antibody. In order to implement an immunoassay on-chip, the
detection signal should be performed within a short time frame in the order of minutes. By
contrast to immunoassays in bulk, long incubation times on-a-chip may be problematic due
to evaporation or diffusion of the sample to the PDMS pores, as PDMS is permeable to water.
Figure 5.2 a shows the alphaLISA signal at different incubation times. The signal stabilises
only after 90 min incubation and the difference in signal intensity between 5 and 90 min
incubation is nearly 10 times higher. From the plot of signal intensity vs. time for each
of the concentrations shown in Figure 5.2 b it is clear that the signal reaches a maximum
faster for the highest concentrations. If one would like to implement this assay on-chip,
calibration should be performed for each of the measurements, as it was made with IDS and
the measurements on the platereader. The microfluidic device could be modified to add some
calibration points if the measurement is performed by imaging the detection chambers and
calibration points simultaneously [205].
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Fig. 5.2 Effect of the incubation time and antibody concentration on alphaLISA signal. a) Standard
curves of alphaLISA obtained at different incubation times. The measurements were conducted at
25◦C. b) Signal dependency of the time for the different concentrations used in a). c) Standard curves
of alphaLISA with triple the concentration of antibodies, d) shows the signal variation over time when
the concentration of antibodies is triple the original.
Increasing the concentration of antibodies up to 3-times as suggested by PerkinElmer
did not change the signal equilibration significantly. The alphaLISA standard curves at
different incubation times with 3x concentration of antibodies is shown in Figure 5.2 c. The
signal is still increasing with time but the plots of signal vs time shown in Figure 5.2 d
indicate that the slope decreases compared to Figure 5.2 b which indicates that an increase
in antibody concentration accelerates the signal stabilisation. Nevertheless, an increase in
the antibody/donor beads resulted in reduced sensitivity by a factor of 10 with respect to the
original protocol.
Increasing the incubation temperature could potentially help to stabilise the signal the
faster. The experiment conducted at 40◦C shown in Figure 5.3 shows that indeed the signal
stabilisation is faster at this temperature. This may be preferable to do rather than incubating
the samples in the microfluidic device for longer times, with its disadvantage of a higher risk
of evaporation.
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Fig. 5.3 AlphaLISA 1-step protocol at 40◦C, reading at different incubation times.
5.3.2 Comparison of TR-FRET protocols
TR-FRET was the original immunoassay of interest due to its advantages over other assays,
mostly because it is a one-step homogeneous assay and it lacks of dependence on background
conditions. Normally, the signal stabilisation of TR-FRET also depends on the kinetics and
equilibrium between antibody and antigen. The signal stabilisation time for the suggested
PerkinElmer protocol was tested. Figure 5.4 a shows the standard curves at different times
by incubation at 25◦C for 90 min, and after overnight incubation at 4◦C. Even though the
signal keeps increasing over time, it does not change drastically in the first 20 minutes. From
Figure 5.4 b it is possible to see that there is already a signal for higher concentrations from
time 0, but the limit of detection improves with increasing incubation time.
The antibody concentration effect was tested and the results shown in Figure 5.4 c indicate
that the Net FRET signal increases but so does the background signal. The plot shown in
Figure 5.4 d shows that the signal maximum is closer to the values reached at overnight
incubation (Figure 5.4). But it is important to mention that the experiment with an overnight
incubation with 3x antibodies was not measured in order to compare if the maximum signal
was reached or not. What is clear from Figure 5.4 d is that there is compromise of sensitivity,
as the lowest values have the same signal as the control (buffer only).
5.3.3 The optics for TR-FRET on-chip
In this study, we have designed and implemented a FRET microscope with two detection
modes, a camera and a photomultiplier tube (PMT), as shown in Figure 5.5. We have utilised
the same optics as in the platereader, thus the excitation source adequate was a 340 nm LED.
In these experiments the signal was detected at two different wavelengths, the donor emission
5.3 Results and discussion 75
a b
c d
-4 -2 0 2 4
0
200
400
600
800
1000
1200
log [Insulin] (ng/mL)
N
et
 F
R
ET
0 min
1 min
2 min
3 min
4 min
5 min
6 min
7 min
8 min
9 min
10 min
20 min
30 min
40 min
50 min
60 min
70 min
80 min
90 min
100 min
Overnight
0 40 80 120 1080 1120
0
200
400
600
800
1000
1200
Time (min)
N
et
 F
R
ET
0.001 ng/ml
0.003 ng/ml
0.01 ng/ml
0.035 ng/ml
0.103 ng/ml
0.345 ng/ml
1.03 ng/ml
3.45 ng/ml
10.3 ng/ml
34.5 ng/ml
103 ng/ml
345 ng/ml
-4 -2 0 2 4
0
200
400
600
800
1000
1200
log [Insulin] (ng/mL)
N
et
 F
R
ET
0 min
1 min
2 min
3 min
4 min
5 min
6 min
7 min
8 min
9 min
10 min
23 min
33 min
43 min
53 min
63 min
73 min
83 min
93 min
0 20 40 60 80 100
0
200
400
600
800
1000
1200
Time (min)
N
et
 F
R
ET
345 ng/ml
103 ng/ml
34.5 ng/ml
10.3 ng/ml
3.45 ng/ml
1.03 ng/ml
0.345 ng/ml
0.103 ng/ml
0.035 ng/ml
0.01 ng/ml
0.003 ng/ml
0.001 ng/ml
0 ng/ml
0 ng/ml
0 ng/ml
Fig. 5.4 Effect of the incubation time and antibody concentration on TR-FRET signal. a) Standard
curves of the TR-FRET measurements conducted at 25◦C incubation and b) the signal increasing
over time for different concentrations. c) TR-FRET standard curves with triple concentration of
antibodies, at different incubation times and d) shows the signal over time for each concentration
using 3x antibodies concentration.
at 620 nm and the acceptor emmision at 665 nm. In the platform presented here we can
exchange the filters in the filter cube manually. The camera was chosen to visualise the FRET
signal in real time and by visualising it is also possible to focus the detection area of the
microfluidic device. However, when samples of FRET labelled antibodies in the presence of
the antigen at different concentrations (Figure 5.6) were observed, no change in the signals
was detected. Figure 5.6 also shows a fluorescent signal from the antibody pair without the
antigen, and we believe that this background fluorescence is from the donor emmision itself.
We further tried to detect the signal of FRET with the PMT but no signal was detected either.
The images shown in Figure 5.6 were taken in a continuos mode, i.e. the LED was
illuminating during the image acquisition process. We therefore believe that in order to
detect the FRET signal, the acquisition control should be performed in a time-resolved way,
to eliminate all the background fluorescence. Furthermore, these samples were tested on a
platereader to confirm that they had FRET signal, but were injected into the microfluidic
device manually and not under continuous flow, which may cause signal photobleaching.
Europium cryptate (FRET donor) is known for its long-lived fluorescence lifetime and
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Fig. 5.5 Instrument built by Dr Pavan Challa and myself, for testing the signal of TR-FRET on-chip.
The excitation source is a 340 nm LED, the light is reflected through a dichroic mirror to the sample
and is emmision signal is detected with the filter for the donor (620 nm) and acceptor (665 nm). The
camera is used for focusing the signal while the PMT can detect as well, when the beam splitter is
used.
stability, so in principle the signal should remain stable over the image acquisition time
course (2000 ms).
Even though these experiments were challenging, we have information on the optimi-
sation that needs to be performed for the on-chip detection of the FRET immunoassay.
Firstly, the measurement should be performed in a time-resolved manner, to eliminate all
the background fluorescence. Moreover, due to the time dependency of the FRET signal,
it may be necessary to make either incubation on-chip or calibration on the same device,
against the blank and at least two concentrations to have the slope of the curve and the
signals simultaneously to reduce errors. Finally, the platform should be able to exchange
both emission filters automatically. We realised that exchanging the filters manually may
cause some errors due to the time difference. Some commercial microscopes are available to
exchange filters in an automated way, and a code could be written to make the measurement
in a time-resolved manner, by excitation with a pulse and a time delay before acquisition.
The microfluidic device proposed for TR-FRET detection is shown in Figure 5.7 a. The
device has the same geometry of an H-filter, as described in Chapter 2. But integrates an inlet
for antibodies that mix them with the separated fractions just before detection in 2 chambers.
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Fig. 5.6 Test of FRET platform with different antigen concentrations. Fluorescent images of the
FRET-antibody pair with different insulin concentrations from 0 to 100 ng/ml, at 620 and 665 nm. No
change in the net signal at 665 nm was observed with increasing antigen concentration.
In this design, the flow control is made with pulling mode, so only one syringe pump is
needed at the device outlet and the length and with of the channels determine the flow rates
at each of the channels. An schematic of the device seen as a microfluidic network with
analogy to electrical circuits [140] is shown in Figure 5.7 b. In the particular case of insulin,
the antibody to insulin ratio is 9:1. As such, the resistance of the channel of the fractions
(r f 1 and r f 2) and the resistance of the antibody sample ra1 and ra2 are designed in a way that
they mix in a 1:9 ratio. The design is simplified by the geometry of the device, with is split
into 50:50 fractions at the end of the diffusion channel. For a different sample, the device
should be either adapted to the corresponding antibody to antigen ratio, or used in the positive
displacement mode to control the flow rate directly from the syringe pumps. However, this
mode would not be optimal because three syringe pumps would be used, one for the sample,
one for the auxiliary buffer and one for the antibody pair. The FRET labelled antibodies are
usually expensive and the withdrawing mode would be the preferred one, because it does not
have the constraint of injecting the sample with a syringe, which requires a larger volume of
sample.
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Fig. 5.7 A microfluidic device design for IDS oc-chip. a) The microfluidic device has the same
geometry of an H-filter, but is adapted to inject the antibodies and mix them with each of the fractions
in the same device. The detection of the signal for both separated fractions, fnd and fd is made on-chip.
In this example, the flow is controlled with the withdrawing mode, therefore only one syringe pump is
needed and the flow rate is defined by the resistance r of each of the channels. b) The device design
can be seen as a microfluidic network analogous to the electric circuits [140]. In this design, the
resistance are designed to have a ratio of protein to antibody of 1:9, as defined by the protocol of the
TR-FRET.
5.4 Conclusions
In this chapter I have studied two commercial homogeneous immunoassays and varied some
kinetic parameters such as incubation time, antibody concentration and temperature in order
to determine the feasibility of implementing these assays to the on-chip detection of IDS.
The results indicate that, for both assays, a decrease in the incubation time compromises the
sensitivity. It was also shown to be the same for an increase in antibody concentration, where
the signal may stabilise faster but would increase the LDL and LLOQ. Temperature may help
to stabilise the signal faster but it also compromises sensitivity. Nevertheless, an increase in
both temperature or incubation time may result in higher evaporation or diffusion into PDMS
membranes. These results indicate therefore, that in order to implement immunodetection
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for diffusional sizing on-chip, it may be necessary to include calibration points at the sides of
the detection chambers.
We have designed and implemented a FRET platform to perform immunodetection on-
chip. However, we believe that the actual FRET signal should be detected in a time-resolved
way to eliminate all the background fluorescence. A microfluidic device design is proposed
for the on-chip measurements of IDS. The withdrawing mode is preferred due to its lower
sample consumption.

Chapter 6
Effect of the chaperone αB-Crystallin on
insulin aggregation
6.1 Introduction
After being synthesised on the ribosome, the amino acid sequence of a protein is exposed
to the crowded intracellular environment, that may promote misfolding and subsequent
aggregation. As a consequence, protein folding in vivo is typically not a spontaneous process,
and living organisms have evolved a class of proteins, called molecular chaperones, that
counteract the tendency of non-native states to aggregate as a result of cellular stress [208].
Chaperones assist proteins in their correct assembly and disassembly of non-functional
aggregates favoured by molecular crowding, in which the most favoured state is that which
excludes the least volume for all macromolecules present [209]. Moreover, chaperones
can also mediate the toxicity of aberrant protein oligomers, either by direct binding to the
hydrophobic surface responsible for oligomer toxicity, or by conversion of the oligomer
into larger and more innocuous aggregates [210]. Elucidating the exact role of molecular
chaperones in the inhibition or promotion of protein aggregation may lead to new therapeutic
strategies in the prevention and treatment of PMDs.
Perhaps one of the most studied molecular chaperones is the family of highly conserved
stress proteins known as heat shock proteins (HSPs). These proteins are ubiquitous, occurring
in all organisms from bacteria to humans. HSPs have been found to be involved in a multitude
of functions, among them de novo folding, refolding of denatured proteins, oligomeric
assembly and assistance in proteolytic degradation [211]. HSPs are first produced by cells in
response to stressful conditions such as heat shock and while not all members of this family
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Fig. 6.1 Molecular chaperones can cause perturbation of the individual microscopic steps of the
aggregation process. Schematic representation of the analysis of the global kinetic profiles of protein
aggregation in the presence of molecular chaperones provides quantitative information on the specific
microscopic steps altered. For example, different mechanisms (a-c) lead to different expected global
kinetic profiles. Reproduced from [213].
are stress inducible, there are some that respond well to a variety of stresses, such as cellular
energy depletion, extreme concentrations of ions, gases and various toxic substances [212].
A two-step strategy might be applied to understand how chaperones can perturb protein
aggregation, such as the one used to study the effect of Zn2+ ions on Aβ aggregation [169].
The kinetic approach consists of characterising the mechanism of aggregation of the protein
in the absence of the chaperone. Next, the same analysis is repeated in the presence of various
concentrations of the chaperone. This approach allows us to pinpoint the change in protein
aggregation kinetics, as the chaperone may specifically alter a single microscopic event, not
the overall aggregation mechanism as shown in Figure 6.1. Finally, the kinetic analysis must
be complemented with an experimental method to calculate the binding interaction of the
chaperone-protein [214].
6.1.1 alpha B-Crystallin properties
The alpha-crystallins are members of the heat shock protein family. Alpha-crystallin accounts
for about 35% of the protein in the mammalian lens, and particularly in the human lens it
reaches a concentration of 450 mg ml−1 [215]. Although alpha-crystallin is better known for
its chaperone properties, it has also been found to be related with several eye pathologies,
including cataracts, among other conditions [216].
There are two alpha-crystallin genes, alpha A and alpha B. In the mammalian lens, the
concentration ratio of alpha A to alpha B is generally three to one. There is about 57%
homology between the amino acid sequence of alpha A and alpha B [215]. αB-crystallin
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Fig. 6.2 The structure of αB-Crystallin (aBC). a N-terminal, α-Crystallin and C-terminal domains.
Adapted from [217]. b) The 3D structure of truncated aBC (residues 68-162, PDB 3L1G). c) The
dynamic state of aBC. The oligomers consist of a dimeric substructure as the fundamental unit of
oligomers of 10-50 subunits [218].
(aBC) is a small heat shock protein found in several tissues including eye-lens, heart, skeletal
muscle, brain, skin, spinal cord, lung and retina [219]. The three-dimensional structure
of aBC consists of three domains, shown in Figure 6.2 a; an N-terminal domain, a highly
conserved core known as the “alpha-crystallin core domain” and a highly flexible C-terminal
extension consisting of 12 amino acid residues [220].
aBC does not have a defined quaternary structure, but rather a wide range of oligomer
species consisting of 10 to 50 subunits [218] as illustrated in Figure 6.2 c. These species are
capable of interconversion and are found to be strongly dependent on the solution conditions,
such as protein concentration, ionic strength, pH and temperature. Since aBC does not
crystallise even at very high concentrations, the crystalline X-ray structure for aBC has not
been determined to date, yet NMR and small-angle X-Ray scattering (SAXS) studies have
shown that a dimeric substructure comprises the fundamental building block of the oligomers
[221].
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aBC chaperone activity is closely related to the binding of non-native proteins by hy-
drophobic interactions. The correlation between temperature changes and chaperone activity
has been previously studied, yet no significant changes in its activity were observed and the
chaperone function is preserved at temperatures as high as 55-65 ◦C, which indicates that
there is no notable conformational change affecting hydrophobicity [222].
aBC has further been found colocalised with α-Synuclein (aSyn) fibrils in patients with
Parkinson’s disease. This finding led to the study of the mechanism of inhibition of aSyn
aggregation using ThT assays, QCM and NMR, amongst other techniques [223]. The results
demonstrated that despite the weak interaction between aBC and monomeric aSyn, the
chaperone strongly binds to formed aSyn fibrils, inhibiting fibril elongation. A similiar
strategy was used to study the inhibition of Aβ42 aggregation by aBC. The results of this
study revealed that aBC supresses the elongation phase of the peptide fibrils by strongly
binding to the fibrils, perhaps because of the hydrophobic interactions between them [224].
In order to determine the ability of aBC to inhibit protein aggregation, several methods
have been employed. In particular, quartz crystal microbalance (QCM) studies were per-
formed to prove the inhibition action of aBC on insulin aggregation [225]. QCM [226] allows
the monitoring of changes in the number of molecules in fibrils by measuring variations in
their masses. Insulin fibril seeds were attached to the surface of the QCM, and the mass
deposited on the surface was measured following the addition of insulin in the presence and
absence of aBC. By using this technique, it has been possible to investigate the rate of fibril
growth in the absence of nucleation and therefore prove that aBC inhibits the elongation of
insulin fibrils at low pH.
Unravelling the detailed molecular mechanism of the chaperones’ binding to aggregated
protein species and its ability to modulate fibrils may be crucial in the development of
adequate treatments for neurodegenerative diseases. This requires the study of intricate
systems with multiple events occurring simultaneously in a complex environment. A deeper
understanding of aBC’s dynamic oligomerisation along with chemical kinetics will provide
greater insight into the mechanism of the chaperone action.
6.1.2 The hormone insulin and its aggregation process
Insulin is a small protein hormone composed of 51 amino acids produced in the pancreas
and secreted into the blood after meals in response to high blood glucose concentrations.
Because of its propensity to self-assemble in long term storage for its application in diabetes
treatments, as well as after repeated subcutaneous injections, it has been extensively studied.
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Fig. 6.3 a) Schematic representation of the amino-acid sequence of the human preproinsulin molecule,
showing the cleavage sites for conversion from proinsulin to insulin. The signal peptide sequence is
indicated in green, the B chain in red, the connecting peptide (C-peptide) in gray and the A chain in
blue. b) Insulin monomer, c) insulin dimer and d) insulin hexamer. Adapted from [227]. 3D structures
of insulin obtained from PDB (3I40 and 4EWZ).
Insulin is derived from human preproinsulin [228] and consists of two chains connected by
two disulfide bonds and a connecting peptide (C), as shown in Figure 6.3 a, the A-chain (21
residues) which contains an intrachain disulfide bond and the B-chain (30 residues). The
signal peptide is cleaved to form proinsulin during transport into the endoplasmic reticulum
and the C-peptide is cleaved before the secretion of insulin from the pancreatic B cells
[228]. The predominant structure of the monomer (Figure 6.3 b) is the α-helix, with high
flexibility at the N- and C-terminal segments of the B-chain [229]. The physiologically
predominant structure of insulin is normally found as a zinc-coordinated hexamer, formed by
the association of three dimers [135], as shown in Figure 6.3 d. Yet, in the absence of zinc,
insulin forms a dimer (Figure 6.3 c) at low protein concentrations over the pH 2-8 range,
shifting to a tetramer at concentrations higher than 1.5 mg ml−1 [230].
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In vitro aggregation of insulin can occur under specific conditions such as acidic pH,
high temperature (60 ◦C) and increased ionic strength [231]. As its fibrillar structures share
common properties with other amyloidogenic proteins, insulin has been widely used as
a model system to gain insights into protein aggregation processes and their biological
implications. The predominant α-helical structure is converted to a flat β -sheet state upon
fibrillation. While several studies show that the B chain, or a segment of it (LVEALYL),
may be the primary determinant of insulin fibrillation, there is also evidence that the A chain
can contribute [232]. A-chain and the B-chain of insulin can form fibrils on their own and
nucleate the fibrillation of full-length insulin, while the soluble chain peptides are able to
inhibit insulin fibril formation [233].
By using the fluorescent dye ThT, the kinetics of insulin aggregation in bulk was studied
under several variables, among them, the effect of concentration, pH, ionic strength, anions,
the addition of the denaturant urea, and the stabilisers trimethylamine N-oxide dihydrate
(TMAO) and sucrose [234]. A decrease in lag time and faster fibril growth was observed
when increasing insulin concentration. A similar trend was observed when decreasing the pH
from neutral to acidic. Regarding ionic strength, no clear correlation with fibril growth was
found. Unlike the denaturant which decreased the lag time, the stabilisers TMAO and sucrose
showed increased lag times. These results indicated that electrostatic and hydrophobic
interactions control both nucleation and fibril growth. Regarding the fibrillar structure, data
obtained by TEM has shown that the diameter of the fibrils is around 20 nm, which does not
change with increasing incubation times, as opposed to the length which may increase up to
2-3 µm [235]. The physical properties of insulin fibrils were characterised with AFM and
force spectroscopy. The fibrils have a strength of 0.6 ± 0.4 GPa. In addition, a breakage rate
constant was found to be 1.3 · 10−8 s−1, which indicates that a fibril of 10 µm length breaks
spontaneously on average every 47 min [236].
Although insulin fibrils have been extensively studied, no integrated rate law for the
mechanism of insulin aggregation has yet been determined. Macroscopic experiments, along
with microdroplet assays, would provide an ideal technique to calculate the numeric values
of the rate constants for a deeper understanding of the mechanism. A disadvantage of the
macroscopic experiments, such as ThT assays, is that it is very challenging to track individual
nuclei in solution. Thus, volume confinement techniques have been developed in order to
form microreactors with a limited number of nuclei that can be followed over time while
determining the aggregation kinetics of fibrils formed as a result of secondary processes
[110, 237]. Microdroplet experiments of insulin aggregation have demonstrated that primary
nucleation rate depends strongly on system size. By forming different sized droplets it
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was shown that when the system size decreases below a critical volume, the lag time of
aggregation increases significantly, therefore proving that confinement helps proteins to
remain soluble [238].
6.2 Aims
Molecular chaperones play a key role in modulating the aggregation process of amyloido-
genic proteins. aBC has been extensively studied using several methods, yet a detailed
understanding of the underlying mechanistic process of this chaperone remains unclear. In
particular, most commonly used methods in studies involving aBC require an immobilisation
step on a surface, which makes it difficult to determine whether the chaperone plays a role
in the inhibition of primary nucleation in solution. The molecular mechanism of aggrega-
tion reactions in the presence of inhibitors has remained challenging, mostly because the
aberrant aggregation of proteins takes the form of complex networks, with elementary steps
that depend on several species and simultaneous reactions. Nevertheless, an approach to
understand the mechanism by which molecular chaperones suppress protein aggregation is
by identifying which of the reaction steps is perturbed [214]. In this study, a global kinetic
profile analysis of insulin aggregation in the absence and presence of the chaperone reveals
that aBC inhibits primary nucleation and reduces the elongation rate. Hence, microdroplet
experiments were performed in order to confirm the observations made in bulk.
6.3 Results and discussion
Understanding the molecular mechanisms involved in protein aggregation is a multifaceted
problem due to the number of processes that occur simultaneously. However, in the case
of an inhibitor, it can be simplified as it usually supresses the self-assembly process by
potential interaction with the substrate protein in either its monomeric misfolded, oligomeric
or fibrillar forms. As a consequence, either the primary or secondary pathways of the
aggregation process can be influenced by chaperone binding [214]. In this approach, a
model that describes insulin aggregation was first identified and, using this model with the
chaperone, the specific microscopic steps that are perturbed by aBC were determined.
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Fig. 6.4 The rate limiting steps of insulin aggregation. a) The kinetic traces for different insulin
concentrations, by ThT fluorescence at acidic pH and high temperature (60 ◦C). b) Normalised data
with the fitting of a model with saturating elongation and fragmentation, obtained with the aggregation
fitting software Amylofit [109]. c) Half time scaling of insulin aggregation under the same conditions.
d) The scaling of the log (half time) plot with a slope γ of -1/3 which gives an indication of the
mechanism of insulin fibrillation.
6.3.1 The mechanism of insulin aggregation
In order to understand the aggregation process of insulin in the presence of an inhibitor, it
is necessary to first describe the system itself. Insulin aggregation has been widely studied
as a model protein, but so far no detailed mechanism for aggregation has been reported. To
obtain more information on the mechanism, fibril growth from insulin monomer at acidic
pH (1.4) and high temperature (60 ◦C) was measured for several monomer concentrations
from 8.7 µM to 349 µM. The data were subsequently analysed using the approach by Meisl
et al. [109], of performing a global fitting with different models to determine the molecular
mechanism for insulin aggregation (Figure 6.4).
In the approach of Meisl et al. [109], the first step consists of normalizing the raw data,
shown in Figure 6.4 a, because at different monomer concentrations the ThT endpoints would
be different for each of the curves. Afterwards, the half times (Figure 6.4 c) and scaling are
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calculated in order to determine possible models that would fit the data better. For this set of
conditions, the scaling exponent is γ =−13 . This indicates a possible saturating process, either
saturating elongation and fragmentation or saturating elongation and secondary nucleation.
The best fit was obtained with a saturating elongation and fragmentation model (Figure 6.4
b), which describes this range of concentrations well under acidic pH and high temperature
conditions. This model confirms previous studies on insulin aggregation where fragmentation
plays an important role on the mechanism [42, 239].
The best model to fit these data was the saturating elongation with fragmentation, which
means that several processes are implicated in the aggregation of insulin where at high
concentrations of monomer the elongation rate is saturated and fragmentation plays an
important role. Even if fibril fragmentation is a monomer-independent process, the number
of monomers available affect the elongation rate and as fibrils can grow faster, they can
also break more easily and generate new fibrils ends. In aberrant aggregation, primary and
secondary pathways always play a role, but solution conditions determine which one is
the dominant process. In the case of insulin, under the conditions used here, it seems that
elongation and fragmentation are the dominant steps.
6.3.2 Kinetics of insulin aggregation in the presence of aBC
In order to understand the mechanistic step at which aBC inhibits the aggregation of insulin,
experiments using insulin with different molar ratios of chaperone were conducted, and the
chaperone showed an effect of rate reduction at concentrations as low as 10%. The kinetics
of amyloid formation in the presence of an inhibitor can also be analysed with the Amylofit
interface as a perturbation of the rate constants. As insulin follows a model of saturating
elongation and fragmentation, the same model has therefore been used to analyse the data
with the inhibitor. Figure 6.5 a-c shows the possible outcomes resulting from the selective
reduction of each of the microscopic rate constants, or those relevant in the mechanism of
insulin aggregation, primary nucleation (kn), fragmentation (k−) and elongation (k+). The
dots are the experimental data and the continuous lines show the kinetic curves resulting
from simulations when each of the rate constants is affected. The experimental data show
an increase in the lag time without any change in the steepness of the sigmoidal transition,
which suggests a reduction of kn. The fitting values with a reduction in the primary nucleation
constant (Figure 6.5 a) describes the process better. The reduction of k− leads to a change
in the slope but it does not reduce the overall nucleation rate significantly, and as shown in
Figure 6.5 b, this model does not describe the experimental data. Finally, a decrease in k+
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Fig. 6.5 aBC inhibits the primary nucleation and elongation steps of insulin aggregation. (a-c) Kinetic
profiles of the aggregation reactions of a 349 µM sample of insulin in the absence and presence
of increasing concentrations of aBC (0 to 200%, represented by different colours). The solid lines
show predictions for the resulting reaction profiles when a) primary nucleation, b) fragmentation,
and c) elongation are inhibited by the chaperone aBC. The prediction for the case where primary
nucleation in perturbed, fits closer to the experimental data (represented with dots) but the prediction
of fragmentation may also describe the data. d) and e) shows the decrease in the apparent constant
(kapp for primary nucleation and fragmentation). Note that the decrease in kapp for primary nucleation
is larger than for fragmentation.
leads to an extended lag phase and decrease in slope as well. Figure 6.5 c shows that even
though this is not the best fit, it still describes the lag time and a part of the aggregation curve.
This may suggest that the chaperone plays a role in the inhibition of both primary nucleation
as well as elongation. Figure 6.5 d-e shows the change in the apparent constant (kapp)
for primary nucleation and elongation, respectively. The change in the primary nucleation
constant kn is notably larger than the one in elongation k+, which may indicate that under
these conditions the chaperone might interact more strongly with the monomers or prefibrillar
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Fig. 6.6 TEM images of insulin fibrils with varying percentage of chaperone relative to insulin
concentration a) 0 %, b) 10 %, c) 50 % and d) 100 %.
aggregates and result in an extended lag time, than the interaction with fibrils where it would
affect the elongation rate.
Figure 6.6 shows the TEM images of the insulin fibrils in the absence and presence of the
chaperones. The insulin fibrils in the absence of the chaperone are overall longer than the
fibrils with aBC, but with increasing concentration of the chaperone the fibrils seem to form
less clumps than with lower concentrations of the chaperone.
Previous studies with insulin [225], aSyn [223], and Aβ [224, 240] have shown that
aBC prevents fibril growth by binding to the fibril ends. Some studies have shown that aBC
can suppress the aggregation of aSyn from its earliest growth stages most likely by binding
to partially folded monomers [241]. However, it has been unclear whether this molecular
chaperone plays a role in the primary nucleation. The dynamic structure of the aBC oligomers
varies strongly with solution conditions and, in this case, previous studies were conducted
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under acidic pH where both insulin and the chaperone are charged and promote other forms
of interactions rather than chaperone-fibrils ends only. The delay in the primary nucleation
rate may suggest the chaperone either interacts with the monomeric insulin by assisting in
its folding, or interacts with the intermediate oligomeric species, preventing the subsequent
formation of the fibrillar species that increase the ThT signal.
6.3.3 Microdroplet experiments
Most of the previous mechanistic studies indicate that aBC plays a role in the elongation
step [223–225, 240]. The data obtained from the kinetic measurements performed in this
study suggest that the chaperone affect both, the primary nucleation and the elongation
rate of insulin aggregation. Microdroplet experiments allow a direct observation of the rare
nucleation events in each of the droplets, and thus could provide deeper mechanistic insights
into the primary nucleation events. These experiments were challenging mainly because
in order to analyse these data in an automated way, it was necessary to obtain droplets
which are of monodisperse size in order to determine the reaction volume and surface effects.
Moreover, it was also necessary that the droplets in the quartz capillary are in a monolayer to
avoid false positives when analysing the fluorescence intensity of each droplet. In order to
achieve these requirements, I modified the droplet device to produce larger droplets by using
a channel width of 100 µm with flow rate of the aqueous phase of 100-200 µl/h and the
flow rate of the oil phase at 2.5 times the flow rate of the aqueous phase. A schematic view
of the microchip is presented in Figure 6.7 a. The wider channel produces larger droplets
and by occupying a larger volume, they are more likely to be in a monolayer in the quartz
capillary. The larger droplet diameter also reduces the aggregation time, because the number
of monomers per droplet increases with droplet volume. The microdroplets were treated in
the same conditions as in the bulk experiments, i.e. acidic pH and 60◦C, and therefore they
were trapped in a quartz capillary (Figure 6.7 c) to prevent evaporation over the incubation
period. The automated stage of the epifluorescent microscope built by Dr Christopher Taylor
shown in Figure 6.8, allows movement to change the position of the glass slide with the
capillaries, making it possible to take images of the droplets along the full length of multiple
capillaries with different chaperone concentrations in parallel. Usually each condition was
repeated in 3-4 capillaries, and four different conditions (insulin and insulin mixed with
increasing chaperone molar ratios) to obtain 12 to 16 capillaries to track in total. In the first
control experiments aBC alone was also studied but never shown signs of aggregation (an
indicative ThT signal was not observed).
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Fig. 6.7 Schematic description of the microdroplet production for kinetics tracking. a) The microfluidic
device has two inlets, with the outer one for the oil phase and the inner one for the aqueous phase.
The microdroplets are formed at the T-junction of the device and flow to the outlet. b) Brightfield
image of the droplets production. c) The microdroplets are collected in a quartz capillary, which are
sealed with wax and then glued to a glass slide, for observation under the epifluorescence microscope.
Another challenge presented during these studies was that due to confinement in small
volumes, the experiment takes place over the course of four days, in which the droplets
can move around in the capillary. Since the droplets are not completely immobilised, it is
challenging to track the fluorescence intensity of each droplet over time in, an automated
way. By aditionally taking brightfield images at each position, this mobile stage makes it
possible to track the position of every droplet if they move from the original position, as well
as identify if there is evaporation which can cause the droplets to shrink.
Microdroplets with different insulin concentrations were generated in order to determine
the optimal concentration of insulin that aggregates within a reasonable amount of time
(ideally less than 5 days). Figure 6.9 shows the effect of concentration and time on aggregation
process, observed in microdroplets. Note that at a concentration of protein of 1744 µM (10
mg/ml), the aggregation happens within 30 h, and in principle this high concentration could
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Fig. 6.8 Schematic illustration of the automatic stage used for imaging the droplets in the quartz
capillaries. a) Epifluorescent setup built by Dr Christopher Taylor. Image provided by Dr Christopher
Taylor. The glass slide with the capillaries is inside an incubator which enables control of the
temperature and the brightfield and fluorescent images to be taken at different positions over time. b)
A schematic of the reading area and examples of the brightfield and fluorescent images taken each
frame. The green arrows indicate the movement of the automatic stage which allows the tracking the
entire set capillaries, filled with different solutions of insulin and insulin with aBC.
be selected to have faster results. However, in practice this concentration of insulin showed
that after addition of the chaperone, the aggregation rate was accelerated instead of delayed,
even under bulk conditions. As described in Section 6.3.1, a mechanism was described for
insulin within a range of concentrations from 70 to 349 µM, and for purposes of comparison,
the experiments in microdroplets were conducted within the same concentration range.
The experiments of insulin in the presence of aBC seem to show that the chaperone
accelerates the aggregation of the hormone even at low concentrations. Figure 6.10 shows
the intensity map of four different capillaries tracked in the same experiment, each of them
with the same insulin concentration (349 µM) but different molar ratios of aBC from 0 to
50%. Surprisingly, the last capillaries to aggregate were the ones that contain only insulin,
and the first to aggregate are the ones with aBC at 10%. What is also interesting about
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Fig. 6.9 Aggregation of insulin in microdroplets, at different monomer concentrations. Image sections
of the capillaries containing microdroplets with different monomeric insulin concentrations from 174
to 1744 µM (x-axis), at different times (y-axis) monitored by ThT fluorescence. The experiment was
conducted to select an adequate insulin concentration to test with aBC. While the highest concentration
shows aggregation within 20 h, the lowest concentration (174 µM) has not aggregated at 60 h.
this experiment is the presence of a “propagation-like” behaviour, as the droplets seem to
aggregate one after another, in all the capillaries.
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Fig. 6.10 Fluorescence intensity map of insulin aggregation in the absence and presence of aBC. Each
of the maps represents a different capillary, from left to right: insulin, insulin with 1% aBC, insulin
with 10% aBC and insulin with 50% aBC. The y-axis shows the time and the x-axis represents a
different droplet. Note that the capillary with insulin alone is the last one to aggregate. While the
capillaries with aBC aggregate faster, there is no trend that correlates with the concentration of the
chaperone, and the capillary with insulin with 10% chaperone was the first one to aggregate. Note
that there also seems to be propagation between the droplets, i.e. one droplet aggregates after another,
each separated by 1-2 h. The intensity of the pixels represents the fluorescence intensity, which in
some cases decreases mainly due to photobleaching.
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Fig. 6.11 The droplets show a “propagation-like” effect in one direction, one droplet aggregates after
another over the course of one hour.
Figure 6.11 shows different frames of the capillary with insulin alone, which starts
aggregating from the droplet in the top of the capillary and propagates to the adjacent one
over the course of one hour.
The experiment with microdroplets should be validated, by perhaps testing higher con-
centrations of insulin with multiple molar ratios of aBC, from extremely low to high ratios.
The fact that the chaperone seems to accelerate, rather than deacelerate aggregation in the
microdroplets under these conditions could have a number of explanations. Firstly, the
surface-to-volume ratio of the droplets is larger than in bulk, and therefore the surface inter-
action in these experiments may play an important role. In addition to the surface-to-volume
ratio, the interface in the microdroplets is completely different to that in bulk, due the presence
of the fluorinated oil as well as the fluorosurfactant that keeps the droplets stable for days.
For these experiments, a concentration of 4%(w/v) was necessary to prevent the droplets
from coalescing. Furthermore, in microdroplets there is no water-air interface. Finally, the
extreme conditions at which the experiments were performed (pH 1.4 and 60◦C) may affect
the structure of the proteins after 20 h. Even though aBC does not show ThT fluorescence
signal neither in bulk nor in microdroplets, the protein could still denature or dissociate to
smaller fragments that, rather than delay aggregation, may accelerate by co-aggregating with
insulin. Previous studies have shown that while aBC exists as large oligomeric aggregates at
physiological pH, at acidic pH values below 3.4 the chaperone dissociates into denatured
polypeptides [242]. Insulin can also undergo hydrolysis at acidic pH and high temperatures
such as 105 ◦C [243, 244]. Further studies with SDS-PAGE and mass spectrometry, after
the incubation of the droplets, could be performed to confirm the hydrolysis of either of the
proteins in the microdroplets.
The “propagation-like” effect observed in the microdroplets as the intensity map shows
in Figure 6.10, indicates that there is either a thermal propagation effect with the exothermic
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heat of the aggregation process affecting the nearest droplets, or some of the aggregates are
able to interact with the interface of the droplets, which favours the nucleation process in
the adjacent one. What is extremely interesting in this case is that aggregation occurs in the
same direction in all cases, from top to bottom of the capillary, even though the nucleation
events of each capillary start at different times. One possibility is that there was air in one
side of the capillaries and this created an air-water interface with one of the droplets, which
propagates in one direction. Again, these experiments should be validated in order to make
the nucleation events of the droplets independent, with a microfluidic array that traps the
droplets and keeps them static to observe them during the incubation time [245]. These traps
are usually fabricated in PDMS and the reason why such arrays were not used in this study is
because PDMS is permeable to water [246], which would cause the droplets to shrink or even
completely dry after a certain incubation time. This array could be optimised for the parallel
incubation of multiple droplets at a time, and could be adapted for longer incubation times
by placing a glass slide on top of the chamber before curing the PDMS, and by decreasing
the incubation time with a higher concentration of protein and salt.
Overall, this experiment should be validated and if indeed the chaperone happens to
accelerate the aggregation process of insulin in microdroplets, further experiments of protein
stability under these conditions should be performed. The chaperone proamyloidogenic
effect has been reported for clusterin [247] when the substrate protein is in a very large molar
excess. The acceleration effect of α-Crystallin has also been reported for insulin aggregation
in the presence of a reducing agent [248]. The effect of the oil with the fluorosurfactant
should also be tested in a bulk experiment, by adding the oil on top of the sample in the
microplate to see whether the change in the interface has an effect on the aggregation rate.
But in general, this experiment should be optimised to track the full aggregation process in
less than 24 h, perhaps with the addition of a high concentration of salt. The aggregation
processes are extremely sensitive to changes in ionic strength as well as pH, and therefore
these factors should be the same in each of the solutions to have the same conditions in
each of the protein mixtures. If conditions were found where the aggregation process in
the droplets occurs in less than 24 h, a microfluidic trap could be used instead of a quartz
capillary. The use of the microfluidic trap would not only ensure that the nucleation events in
each droplet are independent of each other, but also it would make the data analysis easier as
so far the quartz capillary presents multiple disadvantages, such as droplet movement, air
introduction and in some cases, false positives when the droplets are not in a monolayer.
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6.4 Conclusions
Insulin fibrillation has been studied at acidic pH and 60◦ C, in which the acidic pH induces
aggregation most likely by dissociation of native associations (e.g. dimer) and unfolds the
monomer and makes it more aggregation-prone. In this case, the model which describes
the aggregation of insulin under these conditions involves saturating elongation and frag-
mentation processes, which is in good agreement with previous studies of insulin. This has
allowed for the study of the system in the presence of the chaperone aBC, by perturbation
of the original system and simulations that determine which of the rate constants are the
most affected. The nucleation rate (k+) seems to be more notably affected by the chaperone,
but the elongation rate could also be affected, although the predictions indicate that mostly
primary nucleation is delayed.
The microdroplet experiments show that the chaperone may accelerate insulin self-
assembly under these conditions, but further experiments should be conducted in order to
validate or disprove these results. Nevertheless, the microfluidic device and automatic stage
had been optimised to have an automated data analysis which can provide information on a
larger set of data to study stochastic effects.

Chapter 7
Conclusions
7.1 Immuno Diffusional Sizing
The aim of this thesis was to develop and use novel microfluidic techniques to study the
species and processes involved in amyloidogenic protein aggregation. I have optimised a
microfluidic device for its use with immunoassays. By combining these two techniques, I
have developed a powerful tool for studying disease-related proteins in biologically-relevant
conditions. The method presented here, Immuno Diffusional Sizing, has been determined to
be very sensitive and very specific due to the use of fluorescently-labelled antibodies. The
low volume requirements of the microfluidic system, in addition to the low concentrations
needed for IDS experiments, means that the technique developed is perhaps one of the sizing
methods with the lowest sample consumption to date.
The key advantage of this method is its potential to be used with complex biological
samples, such as brain homogenates, as in many cases purification of a target protein is not
always easy. In this case, the developed platform was applied to the prion protein, which has
been traditionally difficult to analyse. Nevertheless, the method is limited by the availability
of specific antibodies for PrPSc, which made the experiments limited to the resistant form of
the infectious prion, PrPres. However, the size determined of PrPres is substantially larger
than the one of PrPC, but smaller than the size of a fibril, which indicates this particle is a
pre-fibrillar aggregate.
The developed technique has further been applied for a wide range of applications, not
only for the direct measurement of amyloidogenic monomers and oligomers, but also shows
great potential for sizing on-pathway oligomers, as well as post-translational modifications.
As in the case of the prion, the main limitation for studying Aβ40 oligomers was the lack of
an antibody pair specific for the aggregated forms of the peptide. Yet, in the case of aSyn, we
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have demonstrated that the measurement of oligomers is substantially easier with such a pair,
and has potential to study on-pathway oligomers as well as in biological fluids, such as CSF.
The limitation on the availability of a TR-FRET pair can be overcome by using his-tagged
proteins, because there are many anti-his tag pairs commercially available in the market.
Even though the hydrodynamic radius does not provide as detailed information as high-
resolution techniques, such as NMR or X-Ray crystallography, it may be applied for de-
termining the parameters of the aggregation state which can be obtained directly after an
aggregation reaction for instance.
7.2 Towards TR-FRET on-chip detection
In this work, two different commercial immunoassays for human insulin were compared by
varying different parameters such as antibody concentration, incubation time and temperature.
Overall, alphaLISA performed better than TR-FRET in terms of sensitivity. However, the
TR-FRET is still more suitable to adapt to on-chip assays, as it is a one-step assay. We have
designed and implemented a platform to detect the TR-FRET within a microfluidic device,
but no FRET signal was observed by imaging the microchannel with the camera and with the
PMT. This may be resolved by performing time-resolved analysis, similar to the approach
taken for the platereader experiments. The device suggested here is the one used for IDS,
with H-filter geometry, but with modifications to add the antibody pair and mix it with each
of the separated fractions to make the detection just after separation. A key advantage of such
a device would be the reduction in the time-measurement. Nevertheless, calibration against
at least two known concentrations should be performed simultaneously to avoid potential
errors generated by the time dependency of the signal.
7.3 Chaperone interactions with insulin
The global kinetic analysis of the insulin data reveals that the hormone follows a mechanism
of fragmentation with saturating elongation at relatively high concentrations up to 349 µM.
By correctly describing the molecular mechanism of insulin assembly, I have been able
to predict what happens when an inhibitor is present during the process of fibril growth.
Previous studies have reported that the chaperone aBC plays an important role by suppressing
fibril elongation, but a complete description of the role of aBC in primary nucleation has
been absent. Adding the chaperone delays the self-assembly of insulin by preventing primary
nucleation at acidic pH. The predictions with simulations show that this mechanism describes
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the experimental data. It may occur by either interaction of the chaperone with the insulin
monomer which prevents it from self-associating, or by interaction of aBC with the pre-
fibrillar, oligomeric species and preventing their transition to mature fibrils.
The data obtained with microdroplets shows that the chaperone may have an acceleration
rather than inhibition role in the process of insulin aggregation in small volumes, such as
the ones of microdroplets. These conditions differ to those in bulk, not only by the volume
and the volume-to-surface ratio, but also in the kind of interface as well as the number of
nuclei available. While in bulk experiments the interface is water-air in the surface and
water-polyestyrene in the sides and bottom of the microwells, in microdroplets the interface
is mostly fluorinated oil and fluorosurfactant. The confinement of protein in small volumes
significantly delays the rate of aggregation, which occurs within a couple of hours in bulk and
in a minimum of three days in the droplets. This made the experiments with the chaperone
quite challenging as finding conditions where the chaperone has a visible effect on the insulin
self-assembly, but happens during a reasonable time-scale requires optimisation. Further
experiments should be performed to confirm or disprove this effect.
7.4 Outlook
7.4.1 IDS
We have optimised and implemented a device suitable to separate molecules and collect them
for analysis with immunochemistry.
A clear improvement to the IDS method would be to develop a correct optics setup to
be able to perform the diffusion and the immunodetection on the same chip, which would
not only save time but would also decrease the sample consumption and probably decrease
the error in measurements. However, in some cases the immunoassays require either long
incubation times or a pre-treatment before analysis with the antibodies. For example, in
the TR-FRET assays to detect PrPC, an overnight incubation stabilised significantly the
signals and reduced the standard deviation of each sample. In the case of PrPres, the detection
was conducted with an ELISA assay, which requires multiple washing steps, as well as
denaturing/re-folding steps that can only be performed off-chip. In these cases, a device that
allows collection of a relatively large volume of sample is the preferred one. An interesting
experiment with prions would be to determine the infectivity of the separated fractions,
because it would provide information whether the larger or smaller species are the most
infectious ones.
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The device design also expands the application of separation to couple it with several
techniques that would otherwise be difficult to perform on-chip. For example, it would
be interesting to pre-separate a complex heterogeneous sample before analysis with mass
spectrometry, and determine which species are in the high and low-diffusivity fractions. The
separation of an heterogeneous sample could also be performed before analysis with AFM,
for example, which would therefore allow to resolve which species are present in each of the
fractions and if compare the size of them to the average radius provided by diffusional sizing.
In the Aβ40 experiments, the method was coupled to SEC in order to investigate the
size of on-pathway oligomers. This separation technique would not be necessary with a
FRET pair specific for the oligomers. However, with such a pair, IDS could be coupled
to a second microfluidic device that worked as an “oligomer-generator”. If the “oligomer-
generator” is completely coated with fibrils, monomeric protein can be flowed through it
to generate oligomers and by coupling it with IDS, information of the species’ size could
be obtained. aSyn might be an interesting system to test, because under certain solution
conditions its mechanism of aggregation is predominantly by secondary nucleation, and it
could be interesting to obtain the size of these secondary nuclei generated in a microfluidic
reactor. Besides, the FRET pair for aggregated aSyn is commercially available and would
not have interference from the monomeric protein that would be in excess to the oligomers.
Another improvement to this technique would be to couple it with a second separation
method in order to resolve all the components in the mixture. For example, it would be
interesting to couple it with electrophoretic separation to resolve the size distribution of the
components rather than just measuring the average radius. But other separation techniques
can be adapted to microfluidics, for example capillary electrophoresis or molecular-affinity
extraction [249]. This would also help to perform better analysis of complex samples,
such as blood. IDS could also be coupled with a pre-concentration technique, to detect
low-concentration analytes, such as the amyloid oligomer species present in CSF.
7.4.2 Towards TR-FRET on-chip detection
The optics for TR-FRET on-chip were tested with a camera and PMT for detection and no
FRET signal was observed. The main limitation could be that these readings are performed
in a continuous way rather than in a time-resolved manner, as it has been performed in
the platereader experiments. The system should be optimised to allow measurements in an
automated manner, such as a) the filters of both emission channels are exchanged quickly,
and b) the excitation is a pulse and the detection is made just after. In the setup described in
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this work, the change of the emission filters was performed manually which could lead to
errors when doing a proper measurement, the emission filters should be exchanged rapidly
in the order of seconds. The time resolved measurement can be conducted in an automated
way by developing a code that controls the excitation source (LED) and the detection system
(camera/PMT). Such control could be developed with a script in python, for example. The
excitation source could also be exchanged for a laser rather than a LED, to enhance sensitivity.
The microfluidic device suggested in this work for IDS with on-chip detection integrates
two detection chambers for each of the separated fractions. The geometry of the chambers
is designed in order to have a uniform signal in the whole detection area. The TR-FRET
signal for insulin was observed in the platereader even after 5 minutes of mixing it with the
antibodies, but in the microfluidic device it might be possible to detect immediately after
mixing. A design than enhances mixing could also be implemented in the device to observe
signal faster and this would open vast possibilities to study the kinetics of the antigen binding
to antibodies.
7.4.3 Insights into the role of aBC in insulin aggregation
The microdroplets experiments have not yet confirmed if aBC indeed plays an important role
in the primary nucleation rate. Further experiments could be performed to understand in
detail the main interactions of aBC with the different species of insulin formed during the
aggregation process. For example, it could be interesting to determine the binding constants
of aBC with insulin monomers, oligomers and fibrils at the same pH conditions to determine
which interaction is the strongest. Another possible experiment is the addition of a significant
amount of seeds (above 40%), in which the role of primary nucleation can essentially be
neglected, and then aBC would only inhibit the elongation rate. It would be interesting to
prove if the delay of the chaperone is significantly affected or the main role of the chaperone
is with pre-fibrillar species.
Further experiments should be performed in order to prove or disprove the acceleration
effect of the chaperone on the microdroplets. It may even be possible that after a certain time,
instead of denaturing, a fraction of either of the proteins is hydrolysed and the fragments co-
aggregate and the effect of acceleration is mainly due to co-aggregating species. Experiments
with SDS-PAGE and mass spectrometry could help to understand if indeed the proteins are
hydrolysing or co-aggregating.
The “propagation-like” effect in the droplets could be avoided by doing the experiment in
a microfluidic array that keeps the droplets spatially separated. If such a device is fabricated
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with a glass slide on top of the channels, evaporation could be reduced and with concentrations
of protein and salt high enough to observe the aggregation within a couple of hours, the data
analysis of the droplets may even be easier than the current system of the quartz capillary.
In general, the concentrations and conditions used in this study could be optimised
to reach aggregation within a couple of hours instead of days. This would avoid several
drawbacks such as data analysis problems, and undesirable effects in the proteins like
hydrolysis. It would also be interesting to apply the droplets to other proteins and inhibitors,
for example with the Aβ peptide in the presence of small molecules which are specific for
primary nucleation [21].
Appendix A
A.1 Calculation of Net FRET signal of the POM FRET la-
belled antibodies
PrP experiments were done with Eu-POM1 and APC-POM19 antibodies. The sample was
measured in quadruplet wells. The Net-FRET of each well were obtained by backgroung
substraction (P-value) with the following expressions:
P-value =
APC channel
Eu channel
(A.1)
APC channel = MeanAPC alone−MeanDetection buffer (A.2)
Eu channel = MeanEu alone−MeanDetection buffer (A.3)
Net FRET = [APC channel]−P× [Eu channel] (A.4)
[APC channel] =Value−MeanAPC alone (A.5)
[Eu channel] =Value−MeanDetection buffer (A.6)
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A.2 RML-BH digestion conditions
1 2 3 4 5 6 7 8 9 10 11 12
PrPres
26 kDa-
35 kDa-
Fig. A.1 Western Blot of digested Tg20-RML and Tg20 BH at different PK concentrations and
incubation times, details of the samples are shown in Table A.1. Detection antibodies are POM-1 pool
in TopBlock 1%/PBS-T and HRP-Goat anti mouse IgG in TopBlock 1%. The selected fractions for
the experiment were 3 and 4.
Gel position 1 2 3 4 5 6
Sample Marker Tg20 RML Tg20 RML Tg20 RML Tg20 RML Tg20 RML
10% BH/µl 3 17.5 17.5 17.5 17.5
PK conc/µg/ml non 25 50 25 50
Inc. time/hrs non 2 2 4 4
Gel position 7 8 9 10 11 12
Sample Marker Tg20 Tg20 Tg20 Tg20 Tg20
10% BH/µl 3 17.5 17.5 17.5 17.5
PK conc/µg/ml non 25 50 25 50
Inc. time/hrs non 2 2 4 4
Table A.1 Different conditions of Proteinase-K concentration and incubation times for RML BH
digestion.
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Fig. B.1 Spectra of the filters and calibration dye used to build a FRET setup. a) Excitation filter
LP 341 nm, and singleband emission filters 625/15 nm and 661/25 nm, b) Dichroic mirror and c)
propidium iodide excitation and emmision spectra.
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